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1. Introduction  
1.1. Lung development  
Lung development is a delicate and tightly regulated process which aims to create an organ in 
which air flow and blood flow are unified to allow the central function of gas exchange and 
oxygenation of the blood. Accordingly, two main systems are combined in the lung: the 
airway and the blood vessel systems. These two systems develop in parallel during the 
different stages of lung development. A variety of different cell types and structural 
compartments of the lung interface with one another to support this central function of gas 
exchange. For example, the surface tension of each single alveolus has to be reduced to 
prevent collapse of the gas exchange region. This is facilitated by surfactant production by 
alveolar type two cells, and secretion of surfactant into the surface mucoid liquid layer 
(Rugonyi et al., 2008). Furthermore, the lung has to be cleared of invaded particles which 
accumulate in the lung surface mucus. This is achieved by the coordinated movement of the 
cilia of the ciliated bronchial epithelial cells. Thus, during lung development, each single cell 
has to differentiate into a certain cell-type with a given phenotype to facilitate its individual 
impact on lung function. To characterise the different developmental processes involved, lung 
development has been divided into six different stages. 
1.1.1. Stages of lung development 
The six different stages of lung development begin with the first appearance of the tracheal 
bud in the developing embryo at gestational day 26 (Burri in: McDonald, 1997 p. 3-4), and 
last until early childhood. The early and prenatal stages comprise the embryonic, the 
pseudoglandular, the canalicular and the saccular stages (Figure 1). During these stages, the 
primitive airways and blood vessels are laid down in the surrounding interstitial mesenchyme, 
which gives rise to the so-called primary septa. Maturation of the airway system and the 
capillary network, respectively, is accompanied by a thinning of the interseptal mesenchyme. 
The fifth stage, the alveolar stage, begins shortly before birth and overlaps with the final stage 
of microvascular maturation which starts postnatally (Zeltner and Burri, 1987). In particular, 
the completion of alveolar formation takes place during the early postnatal phase, and it is still 
a matter of debate whether this process continues late into postnatal life (Alescio and Cassini, 
1962; Burri, 1997).  
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1.1.1.1. The embryonic stage  
The embryonic stage comprises the early phase of the first 1-7 weeks after fertilization. Most 
organs are laid down during this period. At gestational day 26, a ventral outpouching of the 
forgut initiates lung development. The appearance and deepening of the laryngotracheal 
grooves which start to separate the lung bud from the prospective esophagus, gives rise to the 
lobar bronchi after elongation and dichotomous division of the lung bud. The outpouching of 
the forgut is maintained and develops into the hypopharynx, which is the entrance to the 
larynx. At the age of 4-5 weeks, two saccules on the left-hand side and three saccules on the 
right-hand side invade the surrounding mesenchyme. Successive dichotomous division of the 
growing lung succules gives rise to the future airway tree. By the end of the 7th week, the 
airway tree is completely preformed, down to the subsegmental branches. The interaction of 
the mesodermal-derived mesenchyme and the endodermally-derived epithelial system is a key 
function that determines the developmental processes of the embryonic phase (Alescio and 
Cassini, 1962; Spooner and Wessells, 1970; Taderera, 1967). The development of the 
vascular system is also initiated during this stage. Vasculogenesis (the generation of blood 
vessels by endothelial progenitor cells) and angiogenesis (the formation of blood vessels out 
of existing blood vessels) have been described as the two major processes of vascular 
development (Risau, 1997). In particular, the process of angiogenesis has been investigated 
during lung development (Patan et al., 1996). The pulmonary arteries are derived from the six 
pairs of aortic arches. The pulmonary veins grow out of the left atrial portion of the heart. By 
the end of the 7th week, due to the invasion of the epithelial tubes into the mesenchyme, the 
morphological shape of the lung resembles a gland. This marks the beginning of the 
pseudoglandular stage. 
1.1.1.2. The pseudoglandular stage 
This stage was initially described as the “bronchial phase” of lung development. But further 
studies revealed that by the end of this stage at week 17, not all conducting airways have been 
built (Kitaoka et al., 1996). Hence, the terminal brochi are built in this period. The transition 
of the pseudoglandular to the canalicular stage has been described as the period of the birth of 
the acinus (Burri in: McDonald, 1997 p. 4-6). Epithelial cells at the distal part of the airway 
tree have been identified as the precursor cells of the alveolar epithelium in this stage (Ten 
Have-Opbroek, 1979; Ten Have-Opbroek, 1981). These epithelial cells are loaded with 
glycogen which is a key substance required for further cell differentiation (Burri in: 
McDonald, 1997 p. 4-6). Furthermore, ciliated cells, goblet cells and basal cells appear in the 
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central epithelial tube at this stage, and are spread latterly to the more peripheral regions. 
Finally, cartilage is found in the pseudoglandular stage (Bucher and Reid, 1961). Regarding 
vascular development, the growth and division of the arteries occurs like that of the airway 
branching (Hislop and Reid, 1972). In contrast, the veins run in connective tissue septa 
between the airway branches (Verbeken et al., 1996). When the airway branches have formed 
the early acinus, the transition to the cannalicular phase occurs. 
1.1.1.3. The canalicular stage 
This stage begins around week 16 and lasts until the end of week 26. Multiplication of the 
capillaries is one major developmental consequence of this stage. Therefore, it was designated 
the “canalicular” stage, because the lung parenchyma becomes canalized by the growing three 
dimensional capillary network (Burri in: McDonald, 1997 p. 6-8). Later, the airways were 
named canaliculi, which was misleading concerning the initial origin of the name of this 
stage. Indeed, the airways undergo an important change during this stage: the distal primitive 
epithelial system becomes flat, and single glycogen-rich cells differentiate into type I and type 
II pneumocytes (Burri in: McDonald, 1997 p. 6-8). This flattening of the peripheral regions 
and the multiplication of the capillary network leads to the first appearance of the gas 
exchanging tissue. Closer alignment of the capillaries and the flattened epithelial cell layer 
proceeds the maturation of the inter airway space towards the primary septa which are built in 
the saccular stage. At the same time, type II epithelial cells accumulate lamellar bodies, which 
represent the intracellular storage of surfactant. Thus the flattening of the peripheral regions is 
accompanied by the production of surface-active material. Mercurio and Rhodin have 
described that the cells of the undifferentiated epithelium already contain lamellar bodies 
before they differentiate into type I and type II pneumocytes (Mercurio and Rhodin, 1976; 
Mercurio and Rhodin, 1978). This has led to the suggestion that adult type II pneumocytes 
might be the precursors of type I pneumocytes. Taken together, the canalicular stage is a key 
developmental step: due to the appearance of the gas exchange region and the surface-active 
substances, by the end of the canalicular stage, a prematurely born baby in the canalicular 
stage may survive to adulthood (Figure 1). 
1.1.1.4. The saccular stage 
The saccular stage is primarily the stage of widening and growing of the so-called transitory 
airspaces and capillary network (Burri in: McDonald, 1997 p. 8-9). This process is 
accompanied by a reduction of the inter-airway septum thickness which gives rise to the 
primary septum. Within these primary septa a double-capillary network between the adjacent 
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distal air way walls still exists. The thickness of the intra-septal mesenchyme will be further 
reduced in the later alveolar stage: The primary septa will give rise to the first primary alveoli 
by geneneration of thinner secondary septa, which still contain two inter-septal capillaries. 
The earlier saccular stage begins at week 24 and finally overlaps with the alveolar stage 
shortly before birth, by which time it comes to the end. In summary, the saccular stage 
comprises a period of further maturation of the air spaces and capillary network, which gives 
rise to the primary septa. The transition into the alveolar stage begins shortly before birth. At 
birth, the saccular stage ends. During the subsequent alveolar stage, the process of further 
differentiation of the very distal air spaces continues. 
1.1.1.5. The alveolar stage 
The alveolar stage begins shortly before birth at week 36 and ends in the postnatal period 
(Figure 1). In this stage alveoli appear for the first time as outgrowths from the distal 
transitory air spaces which were already laid down in the former stages. The peripheral gas 
exchange regions widen, and the transitory channels and saccules are subdivide into smaller 
units. Elastin deposition in the saccular parts of the lung leads to an outpouching of the 
transitory distal air spaces and gives rise to the first appearance of primitive alveoli (Burri in: 
McDonald, 1997 p. 12-15). The outpouching of the primary septa leads to the formation of 
the secondary septa, which still contain two intra-septal capillaries, but the inter-alveolar 
space is already reduced. Thus, the alignment of the capillaries with the primitive alveolar 
walls becomes closer. Advanced maturation causes the secondary septa to thin out further. 
This thinning out is proceeded by the stage of microvascular maturation, where the inter-
alveolar capillary network continues to develop. 
1.1.1.6. The microvascular maturation stage 
This stage is marked by a strong reduction in the interstitial volume, while the total lung 
volume is constantly increasing. At the same time maturation of the capillary network gives 
rise to the “adult” septa which appear at the end of this stage. The characteristic feature of 
these septa is a single capillary within the inter-alveolar walls. There is strong discussion 
about the morphogenesis of this change from two capillaries to one single capillary in the 
adult septum: Burri et al. demonstrated that the most likely explanation was a process of 
capillary fusion (Burri in: McDonald, 1997 p.17-21), which would result in the formation of 
the pores of Kohn (Weiss and Burri, 1996). Taking together, the maturation of the capillary 
network is a crucial developmental step affecting alveolar maturation. Further preferential 
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growth of the merged areas contributes to further maturation and leads into the adult phase of 
growth of the lung. 
 
 
 
Figure 1: Stages of lung development 
A: Stages of human lung development. The process of lung development can be divided into 
six different stages: the embryonic stage, the pseudoglandular stage, the canalicular stage, the 
saccular stage, the alveolar stage, and the stage of microvascular maturation. Each period is 
characterized by special morphological and molecular changes which are illustrated in this 
scheme. Adapted from (Burri in: McDonald, 1997 p. 2) and (embryology.ch, developed by 
the universities of Fribourg, Lausanne and Berne, Switzerland, update: 15.02.2006)  B: Stages 
of murine lung development. In comparison to the stages of human lung development, the 
murine stages of lung development are distributed differently through the pre- and postnatal 
period. the saccular stage lasts until the postnatal period, and the process of alveolarization 
takes place entirely postnatally. Adapted from (Warburton et al., 2000).  
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1.2. Studying lung development as basis for lung tissue 
regeneration 
Lung development is a highly complex process which is tightly regulated and involves a 
variety of different factors. Growth and maturation of the lung combine different remodeling 
processes: tissue proliferation and differentiation (for example forming the airways and 
capillary networks) occur at the same time as tissue reduction by apoptosis (for example in the 
interstitial mesemchyme and promoting capillary fusion). Even though lung development has 
been studied extensively, the numerous processes involved and the underlying mechanisms 
remain obscure. Since pulmonary diseases are often also accompanied by remodeling 
processes (Capelozzi, 2008; Chin and Rubin, 2008; Henson et al., 2006; Mauad et al., 2007; 
Pardo et al., 2008) a better understanding of the tissue and cell interactions relevant to lung 
development might be helpful, to understand the pathological remodeling processes which are 
activated during pulmonary diseases. Furthermore, a detailed knowledge of the factors 
involved in tissue generation during lung development might reveal targets that could be 
induced therapeutically in lung tissue regeneration in the future. One of those possible targets 
has been addressed in the present study: the HIF 2 α/flk-1 system. 
1.3. The HIF 2 α/flk-1 system 
The HIF 2 α/flk-1 system is a key system mediating physiological and pathological blood 
vessel formation (Carmeliet, 2005; Elvert et al., 2003; Elvert et al., 1999; Flamme et al., 
1997). In particular, flk-1 (fetal liver kinase-1; kinase domain region, KDR; VEGF-receptor 
2) is expressed during embryogenesis in the early primitive vascular network (Flamme et al., 
1995; Risau, 1997; Yamaguchi et al., 1993) and in growing tumor vessels (Carmeliet, 2005). 
It has been demonstrated that flk-1 is regulated by HIF 2 α (Elvert et al., 2003). In mice in 
vivo knock-out approaches of HIF 2 α and flk-1 lead to severe vascular defects generating a 
lethal phenotype (Duan et al., 2005; Shalaby et al., 1995). Furthermore, HIF 2 α is highly 
expressed in the lung (Ema et al., 1997) and plays a critical role in lung development, since 
loss of HIF 2 α led to infant respiratory distress syndrome which could be overcome by 
intratracheal postnatal or intrauterine administration of VEGF (vascular endothelial growth 
factor) (Compernolle et al., 2002). This suggests that the role of the HIF 2 α/flk-1 system is 
not restricted to the development of vascular system. Furthermore, it has been described that 
interactions between the mesenchyme, early endothelial progenitor cells and primitive 
epithelial cells are important to regulate stages of lung development (Burri in: McDonald, 
 1. Introduction  16 
1997 p. 3-4). In particular for the VEGF/VEGF receptor system, the importance of the 
epithelial and endothelial cross-talk has been suggested (Del Moral et al., 2006). Thus, it is of 
relevance to the further understanding of developmental processes of the lung to characterize 
the localization and function of the HIF 2 α/flk-1 system during lung development. 
1.3.1. Flk-1 
Flk-1 belongs to the family of angiogenic vascular endothelial growth factor receptors 
(Mustonen and Alitalo, 1995). This tyrosine kinase receptor family comprises flt-1 (fms like 
tyrosin kinase/VEGF-receptor 1), flk-1 (fetal liver kinase-1/KDR, kinase domain 
region/VEGF-receptor 2) and Flt-4 (VEGF-receptor 3) (Figure 2). Vasculogenesis and 
angiogenesis have been shown to be critically dependent on the VEGF/VEGF receptor system 
(Flamme et al., 1995; Risau, 1997; Risau and Flamme, 1995). Two further members of the 
receptor family are neuropillin 1 and 2 (NRP-1, NRP-2) (Neufeld et al., 2002; Soker et al., 
1998). They have been shown to influence vascular development and to interact with flk-1 
(Figure 2)(Kawasaki et al., 1999; Soker et al., 1998). The VEGF-receptors are activated upon 
ligand binding of the vascular endothelial growth factor (VEGF) family members. Five 
predominant family members have been described: VEGF-A, VEGF-B, VEGF-C, VEGF-D 
and PLGF (placental growth factor)(Figure 2) (Ferrara et al., 2003). Some homologs of VEGF 
have also been identified in the parapoxvirus Orf virus and have been shown to have VEGF-
A-like functions, and these homologs are gathered together and are collectively termed 
VEGF-E (Lyttle et al., 1994). VEGF-A is the key mediator of blood vessel formation. VEGF-
C and VEGF-D are involved primarily in lymphatic angiogenesis (Karkkainen et al., 2002). 
VEGF-B and PLGF contribute to flt-1 function (Olofsson et al., 1998). Alternative splicing of 
VEGF-A leads to four different isoforms consisting of 121, 165, 189 and 206 amino acids in 
humans (Ferrara et al., 2003). The VEGF-A isoforms differ primarily in their capacity to bind 
to the extracellular matrix and cell surface via heparin-binding domains, and thereby generate 
gradients for angiogenic sprouting (Carmeliet, 2005; Ruhrberg et al., 2002). Furthermore, 
VEGF-A belongs to the hypoxia-regulated genes and is regulated by the hypoxia inducible 
factor 1α (HIF-1α) (Liu et al., 1995). Accordingly, it is secreted by hypoxic tissues (for 
example in developing organs or tumor tissue) to attract the growing vessels. During lung 
development, VEGF-A is secreted by peripheral respiratory epithelial cells at the tip of 
developing respiratory tubes (Ng et al., 2001), creating a VEGF gradient that guides the 
vascular network to follow and surround the growing bronchi (deMello et al., 1997). VEGF 
receptors are highly expressed in the mesenchymal endothelial and haematopoetic progenitor 
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cells and in the early primitive vascular network (Carmeliet et al., 1996; Fong et al., 1995; 
Kappel et al., 1999; Shalaby et al., 1995). Accordingly, in vivo gene deletion and mutation 
studies of VEGF, flk-1 and flt-1 demonstrated severe vascular defects with lethal phenotype. 
Loss of a single VEGF-A allele led to a lethal phenotype due to defective blood vessel 
formation (Carmeliet et al., 1996; Ferrara et al., 1996). Analogous effects were observed in 
homozygous flk-1 mutants (Shalaby et al., 1995). Furthermore, mutation of the flt-1 locus led 
to the formation of abnormal vascular channels (Fong et al., 1995). However, flk-1 has been 
shown to be the key mediator of the mitogenic, angiogenic and permeability enhancing effects 
(Clauss et al., 1996; Gille et al., 2001). Thus, flk-1 seems to be the most pivotal mediator of 
endothelial cell differentiation (Flamme et al., 1995; Kappel et al., 1999; Risau, 1997). It is 
also the first receptor known to be expressed in the primitive mesoderm (Yamaguchi et al., 
1993). The flk-1 receptor is a 200 kDa protein with a high affinity for VEGF-A, VEGF-E, 
VEGF-C and VEDF-D (Takahashi and Shibuya, 2005). Flk-1 undergoes dimerization upon 
ligand binding which leads to phosphorylation of different tyrosine residues (Ferrara et al., 
2003; Matsumoto and Claesson-Welsh, 2001). Flk-1 signaling gives rise to a variety of 
vascular cellular functions, such as vascular permeability, cell migration, cell survival, and 
cell proliferation, depending on the phosphorylation site (Figure 3) (Olsson et al., 2006). In 
contrast to the hypoxia-dependent regulation of the ligand VEGF by HIF 1 α, the receptor flk-
1 is regulated by HIF 2 α (Elvert et al., 2003). Within the flk-1 promoter, a HIF 2 α-binding 
site has been demonstrated which is distinct from the hypoxia responsive element [(HRE) the 
common binding site of the HIF transcription factors] (Elvert et al., 2003). HIF 2 α is highly 
expressed in the lung (Ema et al., 1997). In particular, during lung development the 
generation of the vascular system is a key process regulating stages of lung development 
(Burri in: McDonald, 1997 p. 17-22). Angiogenesis and vasculogenesis are initiated at early 
stages of lung development (Gebb and Shannon, 2000; Schachtner et al., 2000). In sum, the 
role of the HIF 2 α/flk-1 system is of key importance in lung development. 
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Figure 2: The vascular endothelial growth factor receptor family 
The vascular endothelial growth factor receptor (VEGFR) family comprises four members: 
VEGFR-1/flt-1 (fms like tyrosine kinase-1), VEGFR-2/flk-1 (fetal liver kinase-1), VEGFR-3 
and neuropilin, which bind the VEGF A, B, C and D ligands with different affinity.  Adapted 
from (Olsson et al., 2006). 
 
Figure 3: VEGFR-2/flk-1 signaling 
Flk-1 is a homodimeric 200 kDa protein. Ligand binding leads to dimerization and 
downstream autophosphorylation of specific tyrosine residues which activates further 
downstream signaling. Cell survival, vascular permeability, cell migration and cell 
proliferation may all be activated via flk-1 signaling. Adapted from (Olsson et al., 2006)  
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1.3.2. The role of flk-1 in lung development 
The importance of flk-1 function in lung development arises from its pivotal role in 
angiogenesis and vasculogenesis. These processes are initiated at early stages of lung 
development (Gebb and Shannon, 2000; Schachtner et al., 2000). Furthermore, it has been 
shown that the development of the endothelial system is crucial for effective lung 
development (Burri in: McDonald, 1997 p. 17-22). However, Gebb and Shannon have 
suggested that tissue interactions between the mesenchyme and the pulmonary epithelium 
play an important role in the developing vasculature, demonstrating that flk-1 expression in 
the early mesenchyme is located close to the pulmonary epithelium throughout early lung 
development. Hence, they suggest that the spatial and temporal expression of flk-1 may direct 
pulmonary vascularization through signals delivered from the epithelium (Gebb and Shannon, 
2000). Accordingly, it has been reported that VEGF-A is secreted by peripheral respiratory 
epithelial cells at the tips of developing respiratory tubes (Ng et al., 2001), creating a VEGF 
gradient that guides the vascular network to follow and surround the growing bronchi 
(deMello et al., 1997). Furthermore, Yamamoto et al. suggested that primary septum 
formation is dependent on reciprocal interactions between the respiratory epithelium and the 
underlying vasculature, involving epithelium-derived VEGF and possibly endothelium-
derived Hepatocyte growth factor (HGF) (Yamamoto et al., 2007). In the same line, Del 
Moral et al., reported that flk-1 knock-down by antisense oligodesoxynucleotides (ODN) in 
embryonic lung cultures resulted in reduced epithelial branching morphogenesis (Del Moral et 
al., 2006). Similar effects were demonstrated by Jakkula et al., where treatment of newborn 
rats with SU 5416 (a specific flk-1 inhibitor) led to decreased alveolarization and decreased 
arterial density (Jakkula et al., 2000). Furthermore, VEGF receptor inhibition has been 
reported to induce lung cell apoptosis and emphysema (Kasahara et al., 2000) and pulmonary 
hypertension and abnormal lung structure (Le Cras et al., 2002). In contrast, Akeson et al. 
demonstrated the disruption of pulmonary vascular assembly and reciprocal defects in 
branching morphogenesis in response to overexpression of VEGF-164 in the pulmonary 
epithelium (Akeson et al., 2003). Further effects of VEGF on lung development were reported 
by Le Cras showing pulmonary hemorrhage and enlargement of the airspaces (Le Cras et al., 
2004). Taken together, these reports demonstrate the crucial role of the VEGF-flk-1 ligand 
receptor system in lung development. Nevertheless, the majority of reports suggests that flk-1 
function primarily impacts the endothelial system, with secondary effect on the epithelial 
system and branching morphogenesis (Figure 4). In contrast, recent reports demonstrate flk-1 
expression in isolated rat fetal alveolar type II cells (Raoul et al., 2004) and in distal airway 
 1. Introduction  20 
epithelial cells in human fetal lungs in vitro (Brown et al., 2001). Accordingly, a direct role of 
flk-1 on the epithelial system might be suggested (Figure 4). Taking into account that HIF 2 α 
is the primary transcription factor of the flk-1 system, the phenotype of HIF 2 α knock-out  
mice supports this suggestion, where Compernolle et al. demonstrated infant respiratory 
distress syndrome due to HIF 2 α deletion in vivo which could be overcome by administration 
of VEGF (Compernolle et al., 2002). Thus, we hypothesized that the HIF 2 α flk-1 system has 
a direct function in the pulmonary epithelium (Figure 4). Accordingly, with regard to flk-1, 
we characterized flk-1 expression during lung development at daily intervals from ED 
(embryonic day) 12.5 until postnatal stages, and in isolated AEC. 
 
 
Figure 4: Possible role of flk-1 in the endothelial-to-epithelial crosstalk during lung 
development 
Flk-1 has been shown to be highly expressed in the developing vascular system (Flamme et 
al., 1995). Accordingly, distinct reports suggest that flk-1 is involved in intercellular crosstalk 
between the endothelial, mesenchymal, and epithelial systems respectively. Signals from the 
developing vascular system may be directing epithelial function and branching 
morphogenesis (Del Moral et al., 2006; Gebb and Shannon, 2000; Yamamoto et al., 2007). In 
contrast, further reports suggest a direct function of flk-1 in the pulmonary epithelial system 
(Brown et al., 2001; Raoul et al., 2004).  
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1.3.3. HIF 2 α  
HIF 2 α belongs to the family of hypoxia-inducible factors. This family comprises three 
different members, HIF 1 α, HIF 2 α and HIF 3 α, each of which form a heterodimer with 
HIF 1 β (also termed ARNT; aryl hydrocarbon nuclear translocator) to translocate under 
hypoxic conditions into the nucleus to initiate the transcription of hypoxia-responsive genes 
(for example erythropoietin, VEGF) (Wang and Semenza, 1993b) via the transactivation 
domains (TAD) (Figure 5A and 5B). HIF 1 α was the first member of this family to be 
discovered (Semenza et al., 1991; Semenza and Wang, 1992; Wang and Semenza, 1995). 
Identification of a minimal hypoxia-responsive element (HRE) in the 3´ enhancer of the 
erythropoietin (EPO) gene led to the identification of a hypoxia- and phosphorylation-
dependent DNA-binding protein (Wang and Semenza, 1993a). Further analysis revealed a 
heterodimeric complex consisting of this protein and HIF 1 β. This complex belongs to the 
basic helix loop helix (bHLH)/Per, ARNT and Sim (PAS) transcription factors. Biochemical 
analysis revealed two highly conserved regions within these HIF familiy members: the bHLH 
and the PAS domains (Figure 5A). The basic region consists of approximately 15 primarily 
basic amino acids which are responsible for direct DNA binding (Moore et al., 2000). The 
PAS domain comprises about 200-300 amino acids which give rise to two weakly-conserved 
regions: the PAS A and PAS B domain (Taylor and Zhulin, 1999). These domains form a 
secondary dimerization interface between the HIF family members, and have additional 
functions in targeting gene specificity, as shown in Drosophila for Trachealess (Trh) and 
single minded (Sim), but the underlying mechanism remains unclear (Zelzer et al., 1997). A 
further characteristic of HIF is oxygen-dependent regulation at the protein level. Under 
normoxic conditions, prolyl hydroxylases 1-3 hydroxylate prolyl residues of HIF α subunits 
(Pro402 and Pro564) within the oxygen dependent degradation domain (ODDD) which leads 
to proteasomal degradation of HIF (Figure 5A and Figure 6). Under hypoxic conditions, 
hydroxylation is inhibited and HIF α subunit levels increase in the cytoplasm (Pugh and 
Ratcliffe, 2003). A further hydroxylation step by the HIF asparaginyl hydroxylase (factor 
inhibiting HIF; FIH) is described, where hydroxylation of an asparaginyl residue prevents the 
interaction of HIF α subunits with the p300 coactivator which is required for transcriptional 
activation (Pugh and Ratcliffe, 2003) (Figure 6). Shortly after the discovery of HIF 1 α, a 
novel cDNA clone was isolated from a murine hypothalamus cDNA library. Using the yeast 
two hybrid system with the bHLH-PAS domain of Arnt as a prey, a protein of 97 kDa and 
exhibiting high homology with HIF 1 α was found (Ema et al., 1997). Sequence analysis 
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revealed a striking similarity to the amino acid sequence of HIF 1 α: the bHLH within the 
amino terminal half comprised 83.9%, the PAS domain 66.5% the following PAS domain 
distal region consisting of aminoacids 345-559 exhibited less similarity, with 36.4% and the 
C-terminal half consisted of variable parts and a small region, composed of amino acids 824-
874, with 63% homology. Chromosomal localization revealed a region distinct from the HIF 
1 α gene locus, which is located on the murine chromosome 12 (Semenza et al., 1996), 
whereas the new protein was localized to murine chromosome 17 (Ema et al., 1997). Analysis 
of dimerization, DNA-binding and transcription-activating properties revealed similar 
properties to HIF 1 α. Coimmunoprecipitation assays and the yeast two hybrid system 
demonstrated that the new protein was coimmunoprecipitated by an anti-Arnt antibody when 
incubated with Arnt, to the same extent as HIF 1 α. Furthermore, both proteins interacted 
selectively with Arnt in the yeast two hybrid system. Hence Ema et al. named the newly 
discovered protein “HIF-like factor” (HLF/later HIF 2 α). Furthermore, the HIF 2 alpha/Arnt 
complex recognized and bound the HRE sequence of the EPO promoter with similar intensity 
to the HIF 1 α/Arnt heterodimer (Ema et al., 1997; Semenza and Wang, 1992). Moreover, the 
transcriptional activation of the HRE sequence of the VEGF promoter by the HIF 2 α/Arnt 
complex resembled the transcriptional activation by the HIF 1 α/Arnt complex. Hence, Ema 
et al. demonstrated that the biochemical and transcription activating properties of HIF 2 α 
were similar to HIF 1 α. The tissue distribution of HIF 2 α and HIF 1 α mRNA in the brain, 
heart, lung, liver, kidney testis and skeletal muscle reveal important differences between these 
two proteins. HIF 2 α was shown to be predominantly expressed in the lung compared to 
other organs. Even though both proteins were expressed ubiquitously in these organs, the 
expression levels of HIF 2 α were generally much higher than those of HIF 1 α at the mRNA 
level. Interestingly, the expression pattern of VEGF which is known to be regulated by HIF 1 
α (Forsythe et al., 1996) was similar to that of HIF 2 α. In particular, during parturition, the 
expression levels of both factors increased. Beginning on ED 17.5, persisting to day P0 and 
becoming highly abundant in the adult lung, VEGF and HIF 2 α were strongly expressed. In 
contrast, HIF 1 α mRNA expression levels were constantly low during lung development 
(Ema et al., 1997). A detailed expression analysis revealed the expression of HIF 2 α in 
vascular endothelial cells in the primitive vascular network at embryonic day 9.5 and 10.5. 
Later stages exhibited the expression of VEGF and HIF 2 alpha in alveolar epithelial cells of 
murine lungs at day P0 (Ema et al., 1997). Some gene deletion studies in vivo exhibited 
different phenotypes. Scortegagna demonstrated an impact of HIF 2 α  on hematopoeisis 
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(Scortegagna et al., 2003b) and ROS production (Scortegagna et al., 2003a). Further studies 
on HIF 2 α deletion revealed a crucial role for HIF 2 α on vascular development and 
remodeling (Duan et al., 2005; Peng et al., 2000). In particular, Duan et al. were able to show 
that overexpression of HIF 2 α in the endothelium of HIF 2 α knock-out mice could rescue 
the vascular phenotype (Duan et al., 2005). In contrast, Tian et al. suggested that the main 
function of HIF 2 α related to the catecholamine metabolism, where HIF 2 α knock-out mice 
suffered from cardiac dysfunction and bradicardia due to a decrease in systemic 
catecholamine levels (Tian et al., 1998). They postulated that HIF 2 α expression in the organ 
of Zuckerkandl leads to an increase in catecholamine production upon hypoxia. Investigations 
by Busselmann et al. supported these suggestions, demonstrating that heterozygous HIF 2 α 
mice are protected against vascular remodeling and pulmonary hypertension due to 
diminished levels of endothelin-1 and catecholamines (Brusselmans et al., 2003). In contrast, 
the same authors described that homozygous HIF 2 α deletion had an impact on the response 
to hypoglycemia, and not on reactions induced by hypoxia (Brusselmans et al., 2001). A 
further function of HIF 2 α was suggested by Guber et al., who demonstrated that loss of HIF 
2 alpha led to anemia, affecting the development of the bone marrow-derived cells (Gruber et 
al., 2007). Taken together, the phenotype of HIF 2 alpha knock-out mice shows a 
heterogeneous pattern. One possible explanation could be the difference in mouse strain 
background. Furthermore, different approaches to gene deletion and differences in the 
experimental setup might have an impact on the phenotype, since different domains of HIF 2 
α might have been deleted. However, Compernolle et al. reported a severe phenotype 
concerning lung function, where HIF 2 α deletion led to severe respiratory distress syndrome 
which could be overcome by the administration of VEGF (Compernolle et al., 2002). 
Furthermore, it has been reported that flk-1, the key regulator of vascular development, is a 
distinct target gene of HIF 2 α (Elvert et al., 2003). Since respiratory distress syndrome is 
generally caused by epithelial cell dysfunction, it might be suggested that the HIF 2 α/flk-1 
system has a direct impact on the pulmonary epithelial system. This idea is supported by 
investigations by Raoul et al. and Brown et al., who demonstrated pulmonary epithelial 
expression of flk-1 (Brown et al., 2001; Raoul et al., 2004). Thus, direct epithelial functions of 
the HIF 2 α/flk-1 system might have impact on lung development. Accordingly, in the present 
study epithelial function of the HIF 2 α/flk-1 system during lung development was 
investigated using a transgenic approach. 
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Figure 5: Transcriptional activation through hypoxia-inducible factors (HIFs) 
A: The structure of hypoxia-inducible factors comprises different domains: the bHLH (basic 
helix-loop-helix ) domain for DNA binding, the PAS (Per Arnt Sim) domains (A and B) for 
interaction between the HIF family members, the TAD (transactivation domain) of the 
carboxy-terminal region (C-TAD) and the amino-terminal region (N-TAD) for transcriptional 
activation. The inhibitory domain (ID) negatively regulates TADs. The oxygen-dependent 
degradation domain (ODDD) regulates protein stability. B: HIF 1 α and HIF 2 α accumulate 
under hypoxic conditions in the cytoplasm and translocate into the nucleus upon binding the 
nuclear protein HIF 1 β. Within the nucleus, bHLH domains bind to the DNA and target gene 
transcription is initiated by the TADs. Normoxic conditions lead to proteasomal degradation. 
Adapted from (Bracken et al., 2003). 
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Figure 6: Hypoxia-dependent regulation of HIF protein accumulation in the cytoplasm 
Under normoxic conditions, HIFs are degraded by prolyl hydroxylation through the prolyl 
hydroxylases 1-3 at specific proline residues. This leads to proteasomal degradation of HIF. A 
further mechanism is regulated by the HIF asparaginyl hydroxylase FIH (factor inhibiting 
HIF). Hydroxylation of an asparaginyl residue prevents the interaction of HIFs with the p300 
coactivator which is required for further transcriptional activation. Adapted from (Pugh and 
Ratcliffe, 2003). 
1.3.4. The role of HIF 2 α in lung development 
HIF 2 α is crucial for vascular development (Duan et al., 2005; Elvert et al., 1999). 
Furthermore, it has been shown to be a crucial transcription factor of flk-1 (Elvert et al., 
2003), which is a key regulator of angiogenesis and vasculogenesis (Risau, 1997; Risau and 
Flamme, 1995). Since the development of the vascular system is a key process regulating 
stages of lung development, the HIF 2 α/flk-1 system impacts a pivotal developmental step. 
Furthermore, Compernolle et al. demonstrated a severe pulmonary phenotype due to 
homozygous HIF 2 α deletion in vivo: HIF 2 α knock-out mice exhibited a severe respiratory 
distress syndrome which could be overcome by the administration of VEGF (Compernolle et 
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al., 2002). Since the respiratory distress syndrome was accompanied by epithelial dysfunction 
including reduced SPC production, a direct role of the HIF 2 α/flk-1 system on the pulmonary 
epithelial system might be suggested. Accordingly, data by Ema et al. and Wagner et al. 
support this hypothesis, demonstrating that HIF 2 α is expressed in the bronchial and alveolar 
regions, respectively of the developing lung (Ema et al., 1997; Wagner et al., 2004). Taken 
together, the HIF 2 α/flk-1 system is crucial for the development of the lung because it is a 
key regulator of the vascular development. However, due to distinct reports on pulmonary 
epithelial cell function (section 1.4), it might be suggested that the HIF 2 α/flk-1 system has 
direct functional impact on the pulmonary epithelial system.  
1.4. The role of pulmonary epithelial HIF 2 α and flk-1 during lung 
development 
Differentiation of the pulmonary epithelial system is tightly connected to the differentiation of 
the vascular system (Burri in: McDonald, 1997 p. 3-21), Since flk-1 is a key mediator of 
blood vessel formation (Flamme et al., 1995; Risau and Flamme, 1995; Shalaby et al., 1995), 
and is regulated by HIF 2 α (Elvert et al., 2003). Several studies illustrated the role of the 
VEGF/flk-1 system in intercellular crosstalk during pulmonary development (Del Moral et al., 
2006; Gebb and Shannon, 2000) Accordingly, these studies point out the relevance of 
endothelial flk-1 mediating effects on the epithelial system, and conversely, epithelial VEGF 
function also impacts the vascular system. It has also been demonstrated that deletion of HIF 
2 α led to a severe disruption of vascular development (Duan et al., 2005). Interestingly, a 
further HIF 2 α deletion study pointed out that global HIF 2 α deletion resulted in a 
respiratory distress syndrome which could be overcome by the application of VEGF 
(Compernolle et al., 2002). Thus, it might be suggested that the HIF 2 α/flk-1 system has a 
direct impact on the pulmonary epithelium. This is supported by studies by Raoul et al. and 
Brown et al., who demonstrated epithelial flk-1 expression in fetal isolated rat alveolar type 
two cells and human fetal lung explants, respectively (Brown et al., 2001; Raoul et al., 2004).  
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2. Hypothesis and aims of the study 
We hypothesize that the HIF 2 α/flk-1 system has a direct impact on the pulmonary epithelial 
system. Epithelial flk-1 expression regulated by HIF 2 α might have direct roles in the 
epithelial system during lung development (Figure 7). To test this hypothesis, the aims of the 
present study were: 
1. Characterization of flk-1 expression from ED 12.5 at daily stages throughout lung 
development until postnatal stages, and in freshly-isolated alveolar epithelial cells from adult 
mice (Ahlbrecht et al., 2008).  
2. Generation of triple-transgenic mice to create an inducible pulmonary epithelial deletion of 
HIF 2 α, to evaluate the impact of epithelial HIF 2 α deletion on lung development in vivo. 
3. Characterization of the phenotype of pulmonary epithelial HIF 2 α knock-out mice, in 
comparison with control mice. 
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Figure 7: Hypothesis: the HIF 2 α/flk-1/VEGF system has a direct role in pulmonary 
epithelial cell function during lung development 
For the vascular system, the expression and function of the HIF 2 α/flk-1 system have been 
reported previously (Duan et al., 2005; Elvert et al., 2003; Flamme et al., 1995). Furthermore, 
flk-1 regulation by HIF 2 α has been demonstrated (Elvert et al., 2003). However reports by 
Brown et al. and Raoul et al. suggest a direct functional role of VEGF on pulmonary epithelial 
cells (Brown et al., 2001; Raoul et al., 2004). Furthermore HIF 2 α deletion led to a severe 
respiratory distress syndrome (Compernolle et al., 2002). Accordingly, we hypothesize that 
the HIF 2 α/flk-1 system has a direct impact on pulmonary epithelial cell function during lung 
development.  
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3. Methodical basis for in vivo transgenic engineering  
3.1. Transgenic animal models 
The ability to investigate single gene function in vivo is accompanied by several advantages 
compared to in vitro cell culture: gene function can be investigated in the context of the whole 
organism, where the impact of the function of a single gene on development can be 
elucidated. Accordingly, the use of transgenic animal models is now widespread, and a 
variety of different approaches have been developed. The key discovery which contributed to 
the transgenics was made by mammalian embryologists. In 1972, Brinstner et al. developed a 
technique for the removal of embryos, embryo culture in vitro and reimplantation of embryo`s 
into foster mothers. Normal embryogenesis was observed in these reimplanted embryos 
(Brinster in: Rothblat, 1972 p. 251-286). This was the essential step in the production of 
chimeric animals, by combining embryonic cells from one embryo with those of another. This 
particular step gained importance because, methods for introducing selectable genes into 
tissue culture were developed by geneticists and virologists at the same time. Further 
techniques to manipulate the embryo were carried out by infecting early embryos with intact 
viruses or viral DNA (Jaenisch, 1976). Combining these two key findings, transgenic 
engineering was born. A variety of different ways to introduce foreign DNA into embryonic 
cell cultures and tissues has been further developed (Palmiter and Brinster, 1986). In 
particular, the pronucleus method (section 3.2) and an alternative method using embryonic 
stem (ES) cells (section 3.3) are currently used to produce transgenic animals. The availability 
of gene transfer technology gave rise to the different transgenic approaches to address 
different questions. In general, gain of function or loss of function can be investigated, either 
by overexpression of a selected gene (section 3.1.1.1) (gain of function) or overexpression of 
a dominant-negative protein or decoy receptor (loss of function). Furthermore, techniques 
exist for the genetic deletion of an endogenous gene to create “knock out” models for an 
alternative approach to study of loss of function (section 3.1.1.2). The third group of 
transgenic approaches comprises the introduction of reporter genes into the genetic 
background (section 3.1.1.3). Using this tool the in vivo localization, expression or function of 
a certain gene and controlling targeted deletion of genes became possible. Further 
sophisticated approaches allow for tissue-specific and inducibility of selected genes (section 
3.1.2.). 
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3.1.1. Constitutive transgenic models 
Stable transgenic animal models can be generated by three different strategies: 1) genes can 
be overexpressed to investigate a gain of function; 2) deletion of genes can be used to 
elucidate the impact of loss of function of a gene on developmental processes or under 
challenge conditions; and 3) reporter genes can be introduced, to localize gene expression in 
vivo. 
3.1.1.1. The overexpression model 
Overexpression models are frequently used to investigate gene function in vivo. The impact of 
overexpression on development (Akeson et al., 2005) or on different pathological stimuli 
(Hanstein et al., 2008) can be investigated. Furthermore, studies on oncogene expression gain 
increasing importance in the elucidation of mechanisms of malignant tumor growth (Acker et 
al., 2005). A variety of different methods for the stable introduction of foreign DNA into the 
genome have been described by Palmiter and Brinster (Palmiter and Brinster, 1986). Due to 
stable and reliable gene expression and targeting, the pronucleus method and the ES cell 
method are currently the most frequently used methods. Furthermore, the constant 
development of transgenic approaches introduced the possibility of cell type-specific and 
inducible overexpression. In addition to the gain of function approaches, investigations using 
loss-of-function models provide a further insight into gene function in vivo and are of 
particular importance for developmental investigations. Overexpressed proteins can also be 
fused to certain amino acid sequences (tags) which can be easily detected by commercially 
available antibodies raised against these tags, facilitating the localization of the expressed 
protein.  
3.1.1.2. The knock-out model 
In vivo gene deletion is a key tool for developmental research. Investigations on the 
phenotype of certain knock-out animals gave rise to the key findings which constituting the 
milestones of developmental research. In particular, the key process of vascular development 
was elucidated by these approaches (Shalaby et al., 1997; Shalaby et al., 1995). However, this 
is only one example out of the variety of knock-out investigations. The discovery of 
homologous recombination (section 3.3.1) in combination with embryonic stem (ES) cell 
culture led to the development of a technique for direct gene integration into a specific region 
of the genome. Accordingly, it became possible to disrupt endogenous gene expression by 
insertion of foreign DNA. Furthermore, site-directed mutagenesis could be integrated into in 
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vivo models by integration of mutated target vectors. A further DNA recombination process 
was used to generate gene deletion: The discovery of the Cre loxP system (section 3.1.2.2) 
gave rise to site-directed gene deletion in vivo. The combination of the Cre loxP system with 
tissue-specific and inducible systems comprises a further key methodology for developmental 
research. The deletion of genes can be combined with the integration of reporter genes to 
investigate localization and the extent of ablation of gene expression (section 3.1.1.3). 
3.1.1.3. Reporter gene transgenic animals/knock-in models 
The possibility of site-directed integration of DNA into the genome gave rise to the so called 
“knock in” method. Reporter genes were integrated into the genome at specific locations. This 
led to the deletion of a specific gene, and also the localization of the replaced gene could be 
investigated by visualization of a reporter gene (Shalaby et al., 1995). Reporter genes are 
genes which code for fluorescent proteins [for example green fluorescence protein (GFP) and 
red fluorescence protein (RFP)] or enzymes [which can be visualized by addition of a 
substrate [for example alkaline phosphatase (AP), β-galactosidase, (β-gal); lacZ gene]. The 
expression of reporter genes can be restricted to a specific cell-type by a specific promoter 
[for example the surfactant protein C (SPC) promoter or Clara cell specific promoter (CCSP)] 
(Perl et al., 2002a) or can be expressed globally if introduced under the control of a 
housekeeping gene promoter (Soriano, 1999). Currently, reporter genes are often combined 
with inducible systems to control the transgene expression (Perl et al., 2002a; Perl et al., 
2002b).  
3.1.2. Inducible tissue-specific overexpression and knock-out models 
The inducible tissue-specific transgene expression or gene deletion comprises a variety of 
methods to investigate gene function during development, and the impact of gene expression 
on different pathological stimuli. Furthermore, the particular cell-type specific role of gene 
expression can be investigated. Phenotypes of global knock-outs can be compared to 
phenotypes of tissue-specific knock-out animals. Furthermore, gene deletion which led to a 
very early lethal phenotype can be investigated by later induction of the gene deletion. Taken 
together, tissue-specific and inducible gene deletion is a key tool to investigate gene function 
in vivo. A variety of different systems has been developed [reviewed by Lewandowski 2001 
(Lewandoski, 2001)], but three systems are currently used for inducible tissue-specific 
expression: the tetracycline-induced system (section 3.1.2.1), and the RU 486 and the 
tamoxifen systems. The tetracycline-induced system is used in this study, hence, it will be 
describe in more detail in section 3.1.2.1. The RU486/tamoxifen system requires another gene 
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targeting system, the Cre-loxP system (section 3.1.2.2) and can be used for inducible gene 
deletion. Mutation of the progesterone-/estrogen receptor leads to a higher affinity for 
RU486/tamoxifen than to the endogenous binding peptides. Furthermore, the Cre 
recombinase is fused to one or two synthetic hormone binding sites which can bind to 
RU486/tamoxifen. Without RU486/tamoxifen the Cre recombinase fusion protein is 
expressed in the cytoplasm and inactive, because the nucleus is its site of action. 
Administration of RU486/tamoxifen causes the nuclear translocation of the Cre recombinase 
fusion protein by binding to RU486/tamoxifen, which also binds to the progesterone/estrogen 
receptor. Accordingly, the entire complex is able to translocate into the nucleus. In the 
nucleus, the Cre recombinase is active and can lead to gene deletion between two inserted 
loxP sites (Lantinga-van Leeuwen et al., 2006; Nagy et al., 2003 p. 291-293). In the present 
study, generation of inducible lung epithelial HIF 2 α deletion was generated using the 
SPCrtTA tetO system (section 3.1.2.1) driving Cre recombinase expression (section 3.1.2.2) 
in SPC-positive alveolar epithelial cells in the presence of doxycycline, which led to HIF 2 α 
deletion due to the inserted loxP sites (section 3.4). 
3.1.2.1. The rtTA tetO system 
The ability to create a system for regulation of gene expression in an “on and off” manner was 
initially discovered by Gossen and Bujard in 1992 (Gossen and Bujard, 1992). They fused the 
control element of a tetracycline resistence operon of Echerichia coli to the activation domain 
of virion protein 16 (VP 16) of the herpes simplex virus, to generate a tetracycline-controlled 
transactivator (tTA). To activate transcription, this tTA protein has to be combined with a 
minimal promoter sequence of the human cytomegalie virus (CMV) which is fused to a tet 
operon sequence. Accordingly, the activation of the expression is initiated by binding of the 
tTA to the tet operon (Figure 8 A). Tetracycline prevents tTA from binding to the tet operon, 
thus its presence inhibits gene expression (Figure 8 A). Fusing a luciferase gene to a tTA-
controlled promoter, Gossen and Bujard were able to show in vitro that luciferase expression 
could be controlled by administration of tetracycline in HeLa cell clones. They showed a 
dose-dependent reduction in luciferase activity with increasing concentrations of tetracycline. 
Thus, this system was also called the tetOff system (Figure 8 A). Removal of tetracycline-
containing media led to an increase in luciferase activity (Gossen and Bujard, 1992). This was 
a remarkable finding because gene expression could be temporally controlled. Nevertheless, 
this model has two major disadvantages: 1) constant tetracycline administration was required, 
and 2) the time-point of induction of the transgene was dependent on the efficacy of 
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tetracycline clearance rate of the HeLa cells. Thus Gossen and Bujard further developed their 
model and published in 1995 the mode of action of the reverse tetracycline transactivator 
(rtTA) system (Gossen et al., 1995). In this model, the VP 16 activation domain was fused to 
a mutated Tet repressor operator of Escherichia coli which gave rise to the rtTA, which 
requires tetracycline derivatives like doxycycline (dox) for DNA binding. Thus, 
administration of dox to HeLa cells constitutively-expressing the rtTA and containing the tet 
operon with the minimal CMV promoter controlling expression of a reporter gene (for 
example lacZ) leads to reporter gene expression (Figure 8 B). Thus, the “tetOn system” was 
born. Furthermore, the ability of inducible transgene expression was combined with tissue-
specific expression of the rtTA in vivo. Constructs were integrated into the mouse genome 
using the pronucleus method (section 3.2). Thus, a complex model was available to address 
developmental and biological questions. Perl et al combined the rtTA system with the SPC 
promoter and the CCSP promoter respectively, to investigate pulmonary epithelial transgene 
expression in mice (Perl et al., 2002a) (Figure 8 C). This model was particularly beneficial 
and important for developmental studies, because transgene expression could be switched on 
at different stages of lung development. Several studies have relied on this model to 
investigate the impact of pulmonary epithelial transgene expression on lung development 
(Akeson et al., 2005; Akeson et al., 2003). 
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Figure 8: Inducible tissue-specific transgene expression 
A: The tTA system: The tetracycline transactivator (tTA) is expressed under the control of a 
tissue-specific promoter (TSP). The tTA binds the tetO7 sequence (seven tandemly-repeated 
19-bp tetO sequences) in the absence of doxycycline (dox) to induce expression of the 
transgene (target ORF [open reading frame]). Upon dox application, binding is prevented and 
the transgene is not expressed (tetOff system). B: The rtTA system. The reverse tetracycline 
transactivator (rtTA) binds the tetO sequence only in the presence of dox to induce expression 
of the transgene (tetOn system). In the absence of dox, the rtTA is not able to bind the tetO 
sequence and expression of the transgene is not induced. Adapted from (Gossen et al., 1995; 
Lewandoski, 2001). C: Tissue-specific overexpression using the SPCrtTA system: the 
expression of the rtTA is driven by the SPC promoter (alveolar epithelial cell-specific 
promoter of the surfactant protein C [SPCp]). Thus, upon dox application, the transgene is 
exclusive expressed in the alveolar epithelial cells. (Abbreviations: tetR: tetracycline 
repressor; VP 16: transactivationdomain of the herpes simplex virus protein VP 16; TATA: 
minimal promoter containing TATA box, pA: poly-adenylation site). Adapted from (Gossen 
et al., 1995; Lewandoski, 2001; Perl et al., 2002b). 
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3.1.2.2. The Cre-loxP system 
In 1998 a key tool for genetically engineering the mouse genome was discovered: Rossant 
and McMahon elucidated the mode of action of the Cre-loxP recombinase system (Rossant 
and McMahon, 1999). Due to the discovery of this system, site-directed DNA recombination 
within two integrated loxP sites became feasible. The DNA recombination could either lead to 
loss-of-function or gain-of-function. In the late ’80s and early ’90s Sauer and Henderson 
demonstrated that the Cre recombinase could work in vitro in eukaryotic cells (Sauer and 
Henderson, 1988; Sauer and Henderson, 1989; Sauer and Henderson, 1990). Accordingly, 
Lakso et al. and Orban et al. demonstrated, that Cre recombinase worked in the mouse model 
as well, when expressed as a trangene (Lakso et al., 1992; Orban et al., 1992). The possibility 
of combining this system with the existing inducible tissue-specific systems gave rise to 
highly sophisticated models of genetically engineering. A remarkable statement by Andreas 
Nagy in 2000 characterized the importance of this finding: “…When we acquired the 
Cre/loxP recombinase system as a tool, we reached the level of sophistication of “no more 
practical limitations” in tailoring the mouse genome…” (Nagy, 2000). 
The Cre recombinase belongs to a family of site-specific recombinases which are collected 
together in the integrase family. The Cre recombinase is a 38 kDa protein of the P1 
bacteriophage and catalyzes recombination between two so-called loxP recognition sites 
(Hamilton and Abremski, 1984). These loxP sites comprise a 34 bp consensus sequence 
which contains a core spacer sequence of 8 bp and two 13 bp flanking palindromic sequences. 
The asymmetric core sequence defines an orientation to the loxP site. The process of 
recombination occurs by the formation of tetramers: each palimdromic sequence of a loxP site 
is bound by a single recombinase molecule. These molecules then form a tetramer and bring 
the loxP sites close together (Voziyanov et al., 1999). After recombination, the new loxP sites 
consist of the two complemetary halves of the prerecombined sites (Figure 9). The outcome of 
the recombination depends on the location of the loxP sites and the actual insertion site. This 
can lead to excision of a sequence, or to inversion of the targeted sequence. Accordingly a 
variety of different consequences is possible, as described by Nagy (2000) (Nagy, 2000): 
Deletion of a functional part of a gene can lead to a knock-out condition. Inversion of a 
sequence could give rise to a new open reading frame (ORF), thus the expression of a new 
protein or mutations can be introduced by recombination. A further tool is to activate reporter 
gene expression by recombination, where the introduction of a stop codon, flanked by the 
loxP sites in front of a reporter gene, can lead to reporter gene expression after recombination 
and stop-codon removal. Taken together, the most common use of Cre recombinase is tissue-
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specific inducible gene deletion, but for particular developmental and biological questions, the 
use of Cre recombinase system is a reliable and well-established tool. In the present study, 
Cre recombinase was inducibly expressed in pulmonary alveolar epithelial cells (Figure 12), 
using the rtTA system under the control of the SPC promoter, as established by Anne Karina 
Perl (Perl et al., 2002b). This Cre expression led to HIF 2 α deletion due to the inserted loxP 
sites, as established by Celeste Simon (Gruber et al., 2007). 
 
Figure 9: Cre recombinase-based excision of a gene 
Excision of a gene can occur upon Cre recombinase-based recombination between two loxP 
recognition sites. They contain an 8 bp core sequence which is flanked by two 13 bp 
palindromic sequences. Each palindromic sequence is recognized by a single Cre recombinase 
molecule. Formation of a tetramer brings the loxP sites together and initiates recombination. 
After recombination the loxP sites consist of two complementary halves of a prerecombinded 
loxP site and the initially flanked sequence is deleted. Adapted from (Nagy, 2000). 
3.2. Generation of transgenic mice by the pronucleus method 
The integration of DNA into the mouse genome by the pronucleus method is the most 
frequently and successfully used method to generate transgenic mice. The foundations of this 
method were laid down by Lin in 1966 (Lin, 1966), who demonstrated that mouse zygotes 
could survive the insertion of a fine glass needle into their pronuclei. Furthermore, the 
injection of macromolecules such as bovine serum albumin (BSA) into zygotes, and their 
transfer into pseudopregnant female gave rise to viable mice. This finding was ahead of time 
because recombinant DNA technologies had not yet been developed. But in 1980 Gordon et 
al. were able to generate transgenic mice (mice stably carrying foreign DNA in their genome) 
by the pronucleus method (Gordon et al., 1980), where foreign DNA was injected into a 
fertilized zygote which was reimplanted into a pseudopregnant female mouse. The offspring 
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comprised the so called founder animals which carried the injected foreign DNA, the 
“transgene”, in their genome (Figure 10). Further reports were published over the following 
years (Brinster et al., 1981; Costantini and Lacy, 1981; Gordon and Ruddle, 1981). Today the 
pronucleus method has become standard procedure to generate transgenic mice (Nagy et al., 
2003; Palmiter and Brinster, 1986), and the maximum permissible size of the integratable 
DNA fragments has increased over time. Strouboulis et al. reported the integration of a 70-kb 
fragment (Strouboulis et al., 1992). The integration of DNA into the genome by the 
pronucleus method results in stable integration of foreign DNA in 10-40% of mice generated 
in the first step, the founders (Nagy et al., 2003 p. 293-294). Integration into the DNA takes 
place randomly (Nagy et al., 2003 p. 293-294). Thus, the integration site and number of the 
copies is not predictable. Accordingly, each generated founder animal has a unique 
integration pattern, site of integration and number of copies. Shortly after injection of the 
DNA into the fertilized zygote, DNA integrates into the genome before the first cleavage. 
Thus, all somatic and germ cells will contain the transgene. If integration is delayed, mosaics 
will be created (Wilkie et al., 1986). Accordingly, the foreign DNA will not be integrated into 
all somatic and germ cells. Thus these founders will give rise to less than 50% of transgenic 
mice, when bred with non transgenic mice. The mechanism of DNA integration is still not 
known in detail (Palmiter and Brinster, 1986) but methods to optimize the process of 
integration have been developed (Brinster et al., 1981; Brinster et al., 1982). Generated 
founder animals have to be characterized, to generate a stable transgenic mouse line (section 
3.2.1).  
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Figure 10: The pronucleus method 
The genetically engineered transgene is injected into a fertilized zygote. The DNA integration 
into the genome occurs randomly. The fertilized zygote is reimplanted into a pseudopregnant 
female mouse. The offspring comprise the founder animals containing the transgene 
integrated within their genome. 
3.2.1. Characterization of founder animals to generate stable transgenic 
mouse lines 
Founder animals are generated by the pronucleus method to create transgenic mice. To 
produce a stable transgenic mouse line, the generated founder animals have to be 
characterized: thus three key features have to be investigated: 1) transgene integration, 2) 
transgene germ-line transmission and 3) transgene expression. Since integration of the 
transgene occurs randomly, and succeeds in only 10-40% of the founder animals (Nagy et al., 
2003 p. 293-294), genomic integration has to be evaluated by genomic PCR to facilitate 
genotyping of the mice. Positive animals are bred with nontransgenic animals to check for 
germline transmission. Genotyping of the resulting offspring shows if the transgen is present 
in the offspring. If transmission is positive, the offspring still have to be tested for transgene 
expression. In case of a constitutive transgene expression the expression can be investigated 
in the first offspring at the RNA and protein level by RT PCR and imunohistology, 
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respectively. Usually tags are integrated into the transgene, to facilitate transgene detection. In 
case of reporter genes, the expression can be visualized. In case of inducible transgenic 
systems, the mice expressing the activator (for example rtTA) are bred with the mice carrying 
the responder transgene which should be induced (for example tetO-Cre). Single transgenic 
animals are bred (rtTA X tetO-Cre) to generate double transgenic mice, which are positive for 
both genes (tTA and tetO-Cre). After induction (for example application of dox), double 
transgenic mice should express the transgene. The double transgenic genotype has to be 
controlled by PCR to distinguish between control mice (single transgenic) and double 
transgenic mice. If single transgenic mice do express the transgene as well, the inducible 
system is leaky. Thus, it is effectively a constitutive system. In case the offspring of a founder 
do express the transgene, the founder can be used to generate a stable transgenic mouse line. 
It has to be kept in mind that mouse lines generated from distinct founder animals must not be 
intercrossed because the integration pattern of the DNA is different and can lead to 
phenotypic differences even though they are carrying the same transgene. 
3.3. Generation of transgenic mice by the ES cell method 
Generation of transgenic mice by the ES cell method is the most common method of site-
specific deletion or gene targeting. In particular, the integration of loxP sites into the genome 
at distinct sites as required for the Cre loxP system is completed by this method. The 
mechanism of homologous recombination (section 3.3.1) allows the specific localization of 
gene targeting. The possibility to combine this method with the Cre loxP system gives rise to 
a variety of different approaches of genetic engineering. In contrast to the pronucleus method, 
the foreign DNA or the so-called targeting vector is transfected into cultured ES cells before 
injection into the blastocyst (Capecchi, 1989). This gives rise to the possibility of screening 
and enrichment of the successfully transfected cells prior to injection. After homologous 
recombination between the target vector and the endogenous DNA, ES cells are screened for 
recombination and enriched by positive and negative selection and clonal expansion (Figure 
11 A and C). Enriched cells are injected into the recipient blastocyste which is implanted into 
a foster mother to give rise to usual development and birth (Figure 11 B). The first offspring 
are chimeric mice. For example, if the ES cells are derived from a mouse homozygous for 
black coat color allel, and the blastocyst is derived from an albino mouse, the offspring will 
have black patches on the white fur because the mice contain cells of both genotypes. 
Breeding of the chimeric mice to albino mice will give rise to some black mice. This indicates 
that the ES cells contributed to the formation of the germ-line. By genotyping of the offspring, 
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germ-line transmission should be controlled. Breeding of heterozygous transgenic mice will 
give rise to 25% of homozygous transgenic mice.  
3.3.1. Alteration of the genome by homologous recombination 
The mechanism of homologous recombination is a key process in generating transgenic 
animals by the ES cell method. It gives rise to site-specific gene alteration. Alterations can 
comprise a variety of different gene manipulations: Gene deletion, site directed mutagenesis, 
reporter gene integration and combination with the Cre loxP system. The targeting vector to 
delete a special gene by homologous recombination has to be constructed in a certain way: the 
vector contains two segments of homologous sequences from the gene of interest which are 
flanking a region essential for the gene function. Inbetween these two homologous sequences 
a positive selection marker (neo gene; resistance marker, resistant to the drug G 418) is placed 
(Figure 11 A and C). After homologous recombination, the positive selection marker will 
replace the gene of interest. Accordingly, ES cells which underwent homologous 
recombination successfully (and became null mutants for the gene of interest), will survive 
the G418 selection. Cells which do not contain the neo resistance gene due to failure of 
homologous recombination will die. Thus, only the null ES cells (-/- ES cells) will survive 
and can be expanded [Figure 11 A and C, (Capecchi, 1989; Nagy et al., 2003)]. Negative 
selection markers have been developed to improve the purity of -/-ES cell cultures: 
Integration of a negative selection marker (tk, thymidine kinase) outside the two sequences of 
homology leads to elimination of all cells with random integration, since random integration 
integrates the whole vector at non-specific regions into the geneome, without homologous 
recombination. This leads to integration of the tk, which is usually excluded upon 
homologous recombination because it lies outside the two homologous regions. Addition of 
gancyclovir into the culture medium will select all cells without tk, and thus, all cells which 
underwent homologous recombination successfully. Cells containing tk will be deleted due to 
the increasing toxicity of gancyclovir mediated by tk expression (Figure 11 C).The effect of 
homologous recombination can be determined by choosing the sequence between the two 
sites of homology because this sequence will be integrated. Thus, a variety of different gene 
alterations can be produced by this method.  
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Figure 11: ES cell method and homologous recombination 
A: Embryo-derived stem cells (ES cells) are transfected with a target vector. Positive and 
negative selection leads to a pure population of targeted ES cells in which the target vector 
has integrated correctly. B: The pure population of targeted ES cells is injected into a 
blastocyst which is reimplanted into a foster mother. The first offspring will comprise 
chimeric mice containing the ES cell genome and the wild type genome in somatic and germ 
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line cells. Further breeding of chimeric mice to wild-type mice will give rise to heterozygous 
mice containing the modified gene locus if germ-line transmission succeeded. Breeding of 
heterozygous mice will give rise to 25% of homozygous mice containing the modified gene 
locus. C: Homologous recombination, and positive and negative selection upon integration 
and homologous recombination. The target vector contains a resistance cassette [for example 
neo gene which is flanked by sequences (H) which are homologous to the sequences (H) 
upstream and downstream of the targeted sequence (X)]. Upon homologous recombination, 
the homologous sequences of the target vector anneal to the endogenous homologous 
sequences flanking the target gene (X). Recombination between these sites leads to the 
excision of the target gene (X) and integration of the resistance cassette containing the the neo 
gene. Accordingly, only the ES cells containing the neo gene will survive the G418 media 
cultivation. Cells lacking the gene will die. As a further strategy to increase purity of the cells 
containing the correctly-integrated vector, the negative selction based on tk and gancyclovir is 
used, where the tk (thymidine kinase) gene is integrated into the target vector outside of the 
homologous regions. Accordingly, the tk gene will be excluded upon correct integration. 
Thus, only cells undergoing random integration without homologous recombination will 
contain the tk gene and will be killed by gancyclovir treatment. Adapted from (Capecchi, 
1989). 
3.4. Generation of inducible pulmonary epithelial HIF 2 α knock-out 
mice  
In this study, the impact of the pulmonary epithelial HIF 2 α flk-1 system on lung 
development was investigated. To address this question, an inducible in vivo knock-out of the 
pulmonary epithelial HIF 2 α gene was created, using a transgenic mouse model approachs. 
The Cre loxP system, in combination with the rtTA system, was used to generate pulmonary 
epithelial HIF 2 α gene deletion. Double transgenic mice carrying the rtTA activator under 
the control of the human SPC promoter and the Cre recombinase controlled by the tetO CMV 
promoter (Perl et al., 2002b) (Figure 12 A) were bred with homozygous HIF 2 α loxP mice 
(Gruber et al., 2007) (Figure 12 B) to generate triple transgenic SPCrtTA/Cre/HIF 2 α loxP 
mice. Further breeding strategies finally lead to triple transgenic, SPCrtTA positive, Cre 
positive and homozygous HIF 2 α loxP mice (Figure 14). Application of dox (by addition to 
the drinking water of the mice) led to expression of Cre in the pulmonary epithelial system. 
The Cre expression drove the recombination between the loxP sites, and hence, deletion of 
HIF 2 α, by creating multiple stop codons within the open reading frame (Figure 12). 
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Figure 12: Generation of inducible epithelial HIF 2 α knock-out mice 
A: Transgene constructs. The rtTA protein was linked to an epithelial cell-specific promoter 
(the SPC promoter). Thus, rtTA is expressed exclucively in AEC. The Cre recombinase gene 
was fused to the tetO sequence and a minimal CMV promoter. Upon dox treatment, rtTA was 
able to bind to the tetO sequence to induce expression of the Cre recombinase. Accordingly, 
Cre recombinase was expressed in the AEC. Adapted from (Perl et al., 2002b). B: In the triple 
transgenic SPCrtTA-tetO-Cre-HIF 2 α loxP mice, exon 2 of HIF 2 α contained contains loxP 
sites. Upon Cre recombination between the loxP sites of the 2loxP allele, a 1loxP allele was 
created which lacked exon 2, and produced a mutated mRNA which contained multiple stop 
codons in-frame, downstream of exon 1. Accordingly, expression of HIF 2 α was disrupted 
(Gruber et al., 2007). 
3.4.1. Generation of triple transgenic homozygous HIF 2 α 1loxP SPC 
rtTA tetO-Cre mice 
To create an inducible pulmonary epithelial HIF 2 α deletion, triple transgenic homozygous 
HIF 2 α 2loxP SPCrtTA-tetO-Cre mice had to be generated. Upon dox treatment, Cre will be 
expressed in the pulmonary epithelial system and DNA recombination will lead to 
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homozygous HIF 2 α 1loxP SPCrtTA-tetO-Cre mice. HIF 2 α and one loxP site will be 
deleted after recombination (Figure 12 B). To generate these triple transgenic mice, double 
transgenic SPCrtTA-tetO-Cre mice (a kind gift from Anne Karina Perl and Jeffrey A. 
Whitsett, Cincinnati Children’s Hospital Medical Center) (Perl et al., 2002b) were crossed 
with to single transgenic homozygous HIF 2 α loxP mice (a kind gift from Brian Keith and 
Celeste Simon Abramson Family Cancer Research Institute, Howard Hughes Medical 
Institute University of Pennsylvania School of Medicine) (Gruber et al., 2007). Offspring 
were genotyped for all the transgenes. The first generation comprised the HIF 2 α loxP locus 
in heterozygous manner or wild-type genotype without the locus. The SPCrtTA locus was 
found in 50% of the offspring because breeding mice were heterozygous for the locus. The 
tetO-Cre locus was present in 50% in case of heterozygous and in 100% in case of 
homozygous breeding mice (Figure 13). Heterozygous HIF 2 alpha loxP mice positive for at 
least Cre or SPC were bred to each other. Genotyping revealed 25% homozygous, 25% wild-
type and 50% heterozygous HIF 2 α loxP mice. The outcome for SPC and Cre referred to the 
breeding outcome of heterozygous breeding pairs. Homozygous HIF 2 α loxP mice positive 
for tetO-Cre or SPCrtTA were intercrossed until a sufficient number of homozygous HIF 2 α 
2loxP SPCrtTA tetO-Cre mice were born (Figure 14). Double transgenic homozygous HIF 2 
α 2loxP mice positive for SPCrtTA or tetO-Cre were used as control animals. Dox treatment 
led to pulmonary epithelial HIF 2 α deletion in the homozygous HIF 2 α 2loxP SPCrtTA-
tetO-Cre mice, but not in the control mice (Figure 14). 
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Figure 13: Influence of the breeding strategy on the genotype of the offspring 
A: Breeding of heterozygous mice (HE) to wild-type mice (WT) gave rise to 50% HE mice 
carrying the transgene (TG) in one allele, and 50% WT mice without TG. B: Breeding of HE 
to HE mice led to 25% WT mice, 50% HE mice and 25% homozygous mice (HO). C: 
Breeding of HO mice to WT mice led to 100% HE mice. 
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Figure 14: Breeding scheme for the generation of homozygous HIF 2 α 2loxP SPC rtTA-
tetO-Cre mice  
A: Homozygous HIF 2 α 2loxP mice (HO) were crossed with heterozygous SPCrtTA 
homozygous Cre mice. This led to 100% heterozygous (HE) HIF 2 alpha 2 loxP mice. Of 
these 50% were positive heterozygous for SPC and 100% were heterozygous for the Cre 
recombinase locus. B: The first generation of HIF 2 α 2loxP HE mice positive for Cre and 
SPC was crossed with each other to generate HO HIF 2 α 2 loxP mice which were positive 
for SPC and Cre. Dox treatment of the HO HIF 2 α 2 loxP SPC/Cre mice led to HIF 2 α 
deletion and generated the HO HIF 2 α 1loxP SPC/Cre mice. Several breeding procedures 
were necessary due to the different distribution of the SPC and Cre allele in relation to the 
2loxP allele. B shows only one possible distribution which leads directly to homozygous 
triple transgenic mice. Others are possible, generating control mice, which lack the SPC or 
Cre alleles. 
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3.4.2. Characterization of the phenotype of epithelial HIF 2 α knock-out 
mice in comparison to control mice 
Epithelial HIF 2 α knock-out mice were characterized by analysis of isolated alveolar 
epithelial cells and whole lung sections. Isolated alveolar epithelial cells of epithelial HIF 2 α 
knock-out mice and control mice were analyzed for changes in protein levels of flk-1 and 
SPC. Lung morphometric analysis (section 4.2.11) was used to determine the impact of the 
epithelial HIF 2 α deletion on lung structure. The number of alveoli, alveolar wall thickness 
and total alveolar volume were measured. Alveolar epithelial cell morphology was 
investigated by electron microscopy on whole lung sections (section 4.2.12). 
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4. Materials and methods  
4.1. Investigations on wild type C57bl 6 mice 
4.1.1. Animals 
C57 black 6 N mice (C57bl 6) were purchased from Charles River. Pregnant C57bl 6 mice 
were ordered at particular embryonic stages to investigate the different stages of lung 
development by in situ hybridization, immunohistology and AEC isolation.  
4.1.2. Preparation of embryonic pups  
Term pregnant C57bl6 female mice were anesthetized with inhaled Isofluran® (Baxter 
Deutschland GmbH, Unterschleißheim, Germany) at a lethal dose. The abdominal cavity was 
opened and embryonic pups were removed. The yolk sac was opened, the placenta was 
removed and embryonic pups were sacrificed on dry ice. Pups were embedded as described in 
section 4.1.3. for whole mount sections, or lungs were removed and embedded as described in 
section 4.1.3. for lung cryosections. 
4.1.3. Preparation of the lung 
Mice were anesthetized with inhaled Isofluran® (Baxter Deutschland GmbH, 
Unterschleißheim, Germany) at a lethal dose. The thoracic cavity was opened after inducing a 
pneumothorax to prevent lung disturbance. The right ventricle was canulated and left atrium 
was opened by incision. The lung was perfused with 10 ml PBS, the trachea was prepared and 
intubated, Tissuetek® (Sakura Finetek, Europe, Zoeterwoude, Netherlands) 1:1 diluted in 
PBS was instilled to fill the airspaces. Filled lungs were taken out of the thoracic cavity, and 
embeded in Tissuetek®. A container filled with isopentane (Roth, Karlsruhe, Germany) was 
placed in a container filled with liquid nitrogen. Lungs were kept in the isopentane fluid to 
slow cool. Lungs were then transferred to liquid nitrogen, and finally stored at -80 °C. Frozen 
sections of the lung tissues and embryonic pups were prepared with a cryotome (Leica CM 
3050, Leica, Wetzlar, Germany) at a thickness of 10 µm. Sections were then used for 
immunohistochemistry (section 4.1.4) and in situ hybridization (section 4.1.5).  
4.1.4. Immunohistochemistry and immunocytology  
Cells or cryostat section were fixed for 10 minutes using acetone or acetone/methanol. After 
blocking with pure goat serum for 1 hour, sections or cells were incubated with primary 
antibodies overnight (flk-1, BD Pharmingen, Danvers, USA; cytokeratin, Dako, USA; 
 4. Materials and methods 49 
proSPC, Chemicon, Temecula, USA). Secondary antibody (goat anti rat Alexa Fluor® 555 
and goat anti rabbit Alexa Fluor®488, Molecular Probes, Invitrogen, UK) incubation and 
incubation with FITC-labeled CD31 antibody (Chemicon) was performed for 1 h. Final 
fixation in 4% paraformaldehyde for 10 min was done prior to nuclear staining (Topro-3®, 
Molecular Probes) for 10 min. Finally, sections and slides were coverslipped with Vectashield 
(Vector Labs Burlingame CA, USA) and analyzed by confocal laser scanning microscopy 
(Leica Type TCS SP 2, DMLFSA, Leica, Wetzlar, Germany) Staining with respective Isotype 
controls with rat and rabbit IgG respectively were carried out with purified rabbit IgG 
(Serotec, Düsseldorf, Germany) and rat IgG (clone 9B5) a kind gift of Georg Breier 
(Department of Pathology Dresden, University of Dresden, Germany).  
4.1.5. In situ hybridization  
Messenger RNA (mRNA) in situ hybridization for flk-1 was performed as described 
previously (Breier, 1999) on frozen sections using [35S]α−UTP-labeled antisense mRNA 
probes. The probes were generated from the murine flk-1 cDNA which was integrated into a 
plasmid containing a promoter for bacteriophage RNA polymerase on each side of the 
integrated cDNA. The flk-1 cDNA-containing plasmid was a kind gift of Georg Breier 
(Department of Pathology, University of Dresden, Dresden, Germany). According to the 
protocol (Breier, 1999), RNA probes were generated by in vitro transcription of the linearized 
flk-1 cDNA containing-plasmid. [35S]α− UTP-labeled sense and antisense probes were 
generated by using 35 S α UTP (Amersham, Freiburg, Germany) during the in vitro 
transcription from DNA to RNA. Template DNA was removed by DNAse I (Boehringer, 
Mannheim, Germany) digestion. Probe purification was assessed by RNA extraction using the 
phenol-chloroform-isoamyl alcohol (PCI) method, and precipitation with tRNA (Sigma, 
Steinheim, Germany) and ammonium acetate (Sigma, Steinheim, Germany). Frozen sections 
were generated from frozen tissue (section 4.1.2 and 4.1.3) and pretreated according to the 
protocol (Breier, 1999). Probes were hybridized to prewarmed sections in a humid chamber 
(50% formamide, Sigma Aldrich, Steinheim, Germany) overnight. Unbound RNA was 
removed by RNAse (Boehringer, Mannheim, Germany) digestion. After dehydration in 
ethanol and air drying, hybridized [35S]α−UTP-labeled sense and antisense probes were 
visualized with a Kodak D 19 developer. Core staining was performed using 0.02% Toluidine 
Blue. Sections were analyzed using a Zeiss Microscope (Zeiss, Axioplan 2 Carl Zeiss, Jena, 
Germany) with light and dark fields. 
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4.2. Generation of triple transgenic inducible pulmonary epithelial 
HIF 2 α knock-out mice 
4.2.1. Transgenic mouse strains 
Double transgenic SPCrtTA-tetO-Cre mice were obtained as a kind gift from Anne Karina 
Perl and Jeffrey A. Whitsett, Division of Pulmonary Biology, Cincinnati Children’s Hospital 
Medical Center, Cincinnati, USA (Perl et al., 2002b). Mice were raised on a FVBN 
background. Single transgenic homozygous HIF 2 α loxP mice were a kind gift from Brian 
Keith and Celeste Simon Abramson Family Cancer Research Institute Howard Hughes 
Medical Institute University of Pennsylvania School of Medicine, Philadelphia, PA 19104, 
USA (Gruber et al., 2007). Mice were raised on an agouti background. Upon Cre 
recombination between the two loxP sites of the 2loxP allele, a 1loxP allele was created 
which lacks exon 2 and produced a mutated mRNA which contained multiple stop codons in-
frame, downstream of exon 1. Accordingly expression of HIF 2 α was disrupted (Gruber et 
al., 2007), (Figure 12). 
4.2.2. DNA–extraction from tailcuts  
DNA extraction was performed with a Qiagen DNeasy Blood and Tissue Kit (Nr: 69506, 
Qiagen, Hilden, Germany). Tail cuts were taken 0.5cm in length, and lysed in 180 µl lysis 
buffer with 20 µl Proteinase K overnight, according to the manufacturer’s protocol. 
4.2.3. PCR for genotyping  
PCR was performed to differentiate the genotype of the different transgenic mice. Two 
transgenic systems were used to create an epithelial tissue-specific, inducible knock-out: 1) 
The rtTA tet on system and 2) The Cre-loxP system. The pulmonary epithelial cell specific 
SPC promoter was used to drive the expression of the rtTA protein. The tetO sequence was 
linked to a minimal CMV promoter upstream of the Cre recombinase. Therefore, three 
different genotypes had to be identified: SPCrtTA, tetO Cre and HIF 2loxP. Concerning the 
Cre-loxP system, loxP sites were integrated upstream of exon 2 of the endogenious HIF 2 
α gene. Hence also in the loxP-system three different genotypes had to be identified: 1) the 
integrated two loxP sites (2loxP), 2) the wild-type (WT) and 3) the knock-out after 
recombination (1loxP). Specific primers and PCR product sizes are shown in Table 1. 
Specific primers were ordered from MWG Biotech (Ebersberg, Germany). PCR was carried 
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out using the AmpliTaq Gold system from Applied Biosystems (Nr: 4311816; Foster City, 
CA, USA) as detailed in Table 2. 
Table 1: Primers for genotyping 
Sequences of forward primers, reverse primers and the PCR product sizes are listed for the 
three transgene loci: SPCrtTA, tetO-Cre and HIF 2 loxP. Concerning the HIF 2 loxP loci, 
three different products are possible: WT (wild-type), 2-loxP (inserted locus) and 1-loxP 
(recombined locus) 
Transgene Forward primer Reverse primer PCR product size 
in bp 
SPCrtTA GAC ACA TAT AAG ACC 
CTG GTC 
AAA ATC TTG CCA 
GCT TTC CCC 
350 bp 
tetO-Cre TGC CAC GAC CAA GTG 
ACA GCA ATG 
AGA GAC GGA AAT 
CCA TCG CTC G 
374 bp 
HIF 2 
loxP 
BK380: CAG GCA GTA 
TGC CTG GCT AAT TCC 
AGT 
BK430: CTA ACA CTG 
TAC TGT CTG AAA GAG 
TAG C 
BK381: CTT CTT CCA 
TCA TCT GGG ATC 
TGG GAC T 
BK380/BK381: 
WT: 430 bp 
2-LoxP: 460 bp 
BK380/BK430 
1-LoxP (KO): 360 
bp 
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Table 2: PCR protocol for genotyping  
Optimized conditions for the transgene detection by PCR of the three transgene loci:  
SPCrtTA, tetO-Cre and HIF 2 loxP. 
  SPCrtTA tetO-Cre HIF 2 loxP 
Initial denaturation 120 s 94 °C 120 s 94 °C 120 s 94 °C 
Denaturation 30 s 94 °C 30 s 94 °C 30 s 94 °C 
Annealing 30 s 60 °C 30 s 60 °C 30 s 58 °C 
Elongation 40 s 72 °C 90 s 72 °C 45 s 72 °C 
Final elongation 300 s 72 °C 300 s 72 °C 300 s 72 °C 
Cycles 35 35 35 
 
 
 
 
 
 
 
PCR products were separated by gel electrophoresis on 1.5% agarose (Invitrogen Nr: 15510-
027, UK) gel, in TAE (1 l 50× TAE: 242 g Tris base, 57.1 ml glacial acetic acid, 100 ml 0.5 
M EDTA, pH 8). For visualization, ethidium bromide (Fluka Nr: 46067, Seelzen, Germany) 
was included in the electrophoresis run, and the gel was examined with the CHEMI GENIUS 
BIO IMAGING SYSTEM (Syngene, Cambridge, UK).  
4.2.4. Induction of transgene expression  
Due to the rtTA system, transgene expression could be induced by dox (doxycycline, Sigma 
Aldrich, Steinheim, Germany) a tetracycline analogue. For in vivo induction, dox was added 
to the drinking water at a concentration of 0.2 mg per liter with 0.2 mg Sodium Citrat per liter 
and 10 g glucose per liter. Expression was induced continouously from the day of conception 
(ED 0). In vitro dox was supplied to the culture medium in a concentration of 1 µg/ml for 48 
h. 
4.2.5. AEC isolation and culture 
Alveolar epithelial cells were isolated as previously described in detail (Corti et al., 1996). 
The cells were cultured for three days in DMEM (Gibco, Karlsruhe, Germany) supplemented 
with 10% fetal calf serum. Cells were washed thoroughly every 24 h and supplied with fresh 
media. Before VEGF-A stimulation, supernatants were removed and subjected to a VEGF-A 
ELISA. Cells were starved for 4 h in serum-free medium before stimulation with 100 ng/ml 
VEGF-A (R&D Systems, Wiesbaden, Germany) for 1 min. The cells were washed after 
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incubation with cold phosphate-buffered saline and lysed in RIPA buffer supplemented with 
Complete™ protease inhibitor cocktail (Roche, Basel, Switzerland). For western blot analysis 
and immunocytochemistry for HIF 2 α, cells were kept in culture for 48 h under normoxic 
and hypoxic (1% of oxygen) conditions. DNA isolation for Southern blot analysis was 
performed after 48 h culture with dox, supplied in the medium at a concentration of 1 µg/ml. 
4.2.6. Southern blot Analysis for genotyping 
DNA from isolated AEC was extracted as described in section 4.2.2. The DNA was digested 
using 10 µl DNA (5 µg), 5.3 µl H2O, 2 µl 10× buffer (as provided with enzyme), 0.2 µl BSA, 
2.5 µl Nco I, (10 U/µl) (Promega, Mannheim, Germany) overnight at 37 °C. The reaction was 
stopped by heating for 10 min to 65 °C. After addition of 6× loading dye, samples were 
loaded onto an 0.7 % agarose gel with ethidium bromide included. The gel was run at 90 V 
until the dye front had migrated approximately 6 cm. The samples were blotted on a Hybond 
N membrane (Amersham, Freiburg, Germany) by capillary transfer overnight. Following 
transfer, the membrane was oven baked at 80 °C for 2 h to fix DNA to the membrane. 
The probe was derived from plasmid kindly provided by Brian Keith and Celeste Simon 
(Abramson Family Cancer Research Institute, Howard Hughes Medical Institute, University 
of Pennsylvania School of Medicine, Philadelphia, USA) by digestion with KpnI and ClaI 
(Promega, Mannheim, Germany). Following purification of the probe by electrophoresis and 
gel extraction, the probe was labeled using the Amersham Gene Images Alk Phos Direct 
Labeling and Detection System (Amersham, Freiburg, Germany). All subsequent procedures 
were carried out according to the manufacturer’s protocol.  
4.2.7. mRNA isolation from AEC 
The mRNA was isolated from AEC after three days of culture in medium with 1 µg/ml dox. 
For mRNA isolation the Qiagen mini kit® (Qiagen, Hilden, Germany) was used. The 
procedure was performed according to the manufacturer’s protocol. The mRNA concentration 
was measured using a Nanodrop® (Thermo Scientific, Wilmington, USA) spectrophotometer. 
4.2.8. RT PCR  
RT-PCR was performed with reverse transcriptase from Applied Biosystems (Foster City, 
CA, USA) using 1 µg RNA as template. Samples were heated at 95 °C for 7 min, the reaction 
mixture was added, and transcription was performed for one hour at 55 °C. cDNA was used 
for PCR as described in section 4.2.3. 
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4.2.9. Immunoprecipitation and western blot analysis  
Immunoprecipitation 
The AECs were lysed in lysis buffer containing 20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM 
EDTA, 1 mM EGTA, 1% Triton X 100, 2.5 mM Sodium-pyrophosphate and 1 mM 
glycerophosphate. Vanadate (1 mM) and the protease inhibitor Complete™ (Protease 
Inhibitor Cocktail, Roche; Nr. 11836170001; Roche, Mannheim, Germany were added freshly 
before use. Antibody (2 µg) was added to each sample, and samples were incubated at 4 °C 
with constant mixing for 1 h. Protein-antibody complexes were precipitated by the addition of 
25 µl of protein A-agarose and an additional hour of incubation. Samples were centrifuged, 
supernatant removed and the agarose pellet washed three times with lysis buffer. After a final 
wash, 30 µl of 2× sample buffer was added to each sample, and the samples were boiled for 5 
min and resolved by gel electrophoresis. 
Western blot analysis  
Cell lysates from freshly isolated AEC and immunoprecipitations were separated on a 6 % 
sodium dodecyl sulphate polyacrylamide gel. Proteins were transferred to a polyvinyl 
difluoride (PVDF) membrane using a wet blotting chamber, and after blocking with 7.5 % 
milk, incubated with primary antibody overnight (anti-flk-1, Cell Signaling Technology, 
Boston, MA, USA dilution 1: 1000; or anti-phosphotyrosine; BD Transduction, Heidelberg, 
Germany; dilution 1: 1000, anti HIF 2 α antibody Novus, Littleton, USA, dilution 1:1000; 
anti proSPC; Chemicon, Hofheim, Germany, dilution 1:1000). Bound antibody was visualized 
with species-specific peroxidase-conjugated secondary antibody (Pierce, Rockford, IL, USA; 
dilution 1: 3000) followed by detection with an incubation for 1 hour and ECL® system, 
(RPN 2132 Amersham, Freiburg, Germany).  
4.2.10. Preparation of cytosolic and nuclear extracts 
For nuclear extraction, all steps were performed on ice. Medium from cultured AEC was 
removed and cells were washed twice with ice-cold PBS, then 1 ml of PBS was added to the 
cell culture dish and cells were scraped using a rubber policeman. The cell suspension was 
transferred into a reaction tube and centrifuged. The supernatant was removed completely, 
and pellets were resuspended in low-salt buffer (three times the volume of pellet) containing 
20 mM Hepes pH 7.9, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 0.2 % NP-40, 10 % glycerol. 
Vanadate (1 mM) and Complete™ (Proteinase Inhibitor Cocktail, Roche Nr:11836170001, 
Roche Mannheim, Germany) were added prior to use. Samples were incubated on ice for 10 
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min, vortexed and centrifuged. The supernatant was designated a cytosolic extract, the pellet 
was resuspended in high-salt buffer (2/3 of the volume used for cytolsolic extraction) 
containing 20 mM Hepes pH 7.9, 420 mM NaCl, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 
20 % glycerol. Vanadate (1 mM) and Complete™ (Proteinase Inhibitor Cocktail, Roche 
Nr:11836170001, Roche Mannheim, Germany) were added prior to use. Samples were 
incubated on ice for 30 min, vortexed and centrifuged. The resulting supernatant was 
designated a nuclear extract. Cytosolic and nuclear extracts were aliquoted and frozen at -80 
°C. The Bradford method was used to determin protein concentration (BioRad Quick Start 
Bradford Dye Reagent, Nr: 500-0205, BioRad, München, Germany). Samples were then used 
for western blot analysis as described in section 4.2.9. 
4.2.11. Lung morphometry analysis 
Lung morphometry analysis was kindly performed by Dipl. Ing. Msc. Biol. Sandeep Nikam. 
 
Lung isolation and volume determination 
The mice were heparinized by an intraperitoneal (i.p.) injection of 500 units of heparin, and 
then sacrificed as described in section 4.1.3. The thorax was opened and the trachea and 
pulmonary artery were cannulated. The lung and heart were flushed with PBS followed by 
perfusion through the pulmonary artery and through the trachea, respectively, with 4 % 
buffered paraformaldehyde (PFA) (Sigma-Aldrich, Seelzen, Germany) with a pressure of 20 
cm and 10 cm H2O, respectively. Afterwards, the trachea was ligated, and the heart and lung 
were resected en bloc from the thorax and fixed in fresh fixative overnight at 4 oC. The 
volume of lung was determined by water submersion method (Scherle, 1970). 
Lung preparation for design-based stereology 
The lungs were prepared for the estimation of various parameters using design-based 
stereology as described by Voswinckel et al., (Voswinckel et al., 2004). Systematic random 
sampling of the lung tissue was performed according to Michel and Cruz-Orive (Michel and 
Cruz-Orive, 1988). The organ was cut into 3 mm slices, dehydrated with a graded series of 
alcohol, and paraffin-embedded. The 3 µm sections were cut on microtome (Microm, 
Germany), and stained with Wiegert Elastin-Fuchselin and Nuclear-Fast-Red-Aluminium 
sulphate (Waldeck GmbH, München, Germany). Each section of every slice from each lung 
was used for quantitative estimation using stereology. Using meander sampling, a collection 
of fields was obtained from each lung slice, thus ensuring that the scanning was done over the 
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whole organ. A two-level procedure was performed for point and intersection counting to 
determine the volumetric parameters and total surface area as given by Howard and Reed 
(Howard, 1998). Lungs were divided in two compartments, non-parenchyma compartments 
(comprising of lumen, wall, and tunica adventitia of airways and vessels) and parenchyma 
compartments (alveolar duct airspace, alveolar airspace and alveolar septum). Furthermore, 
volume fractions of each compartment were estimated. Absolute volumes of the respective 
lung compartments were obtained by multiplication of the total lung volume with the 
respective volume fraction. Total alveolar surface area was calculated by multiplication of the 
surface density of the alveolar septum (surface per unit volume of parenchyma) and the 
absolute parenchymal volume. The surface density of the alveolar septum was estimated from 
the sum of intersections of the test lines (22.5 µm of length) with the alveolar septa and the 
sum of test points hitting parenchymal structures. All stereological analyses were performed 
by means of a computer-based system (connected to a Leica DM6000 microscope (Leica, 
Wetzlar, Germany). 
4.2.12. Electron microscopy 
Analysis by electron microscopy was kindly performed by Prof. Dr. Wolfgang Kummer, 
Institute for Anatomy and Cell Biology, University of Giessen, Germany. 
 
Lungs were fixed via tracheal instillation at a pressure of 10 cm H2O from the right ventricle 
with 2.5 % glutardialdehyde, 1.5 % PFA in 0.1 M phosphate buffer, pH 7.4. Tissue blocks (< 
2 mm) were cut from peripheral lung with a razor blade, washed in 0.1 M phosphate buffer, 
osmicated for 1 h in 0.1 OsO4 in 0.1 M phosphate buffer, transferred to 0.05 M maleate 
buffer, pH 5.2, stained en bloc for 1 h with 1 % uranyl acetate in this buffer, washed again in 
maleate buffer, pH 5.2, and then dehydrated through a graded series of ethanol and embedded 
in Epon (Agar100; Plano, Wetzlar, Germany). Thin sections (70-80 nm) were cut with an 
ultramicrotome (Ultracut E; Reichert-Jung, Heidelberg, Germany), collected on nickel grids, 
and stained with lead citrate. Sections were evaluated with a Zeiss EM 902 transmission 
electron microscope (Zeiss, Jena, Germany). 
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5. Results 
5.1. Flk-1 expression during lung development and in isolated AEC 
of adult mice  
5.1.1. Flk-1 mRNA expression during lung development 
To characterize flk-1 mRNA expression during lung development, we analyzed embryonic 
mouse lungs of C57bl 6 mice at ED12.5 to ED18.5 as well as postnatal days 1 (P1) and 14 
(P14) by radioactive [35S]α− UTP-labeled mRNA in situ hybridization. On ED12.5, flk-1 
expression was restricted to the pulmonary vascular network (Figure 15, black and white 
arrowheads). From ED16.5 onwards flk-1 mRNA was detected in the epithelial cells of the 
branching epithelial tubes (Figure 15, black and white arrows), persisted in the primordial 
bronchi at ED17.5 and spread to the emerging gas exchange regions at ED18.5. At postnatal 
days 1 and 14, flk-1 expression was maintained in the bronchial epithelium, while in the 
alveolar septa expression was increasingly restricted to individual cells (Figure 15, black and 
white arrows). Along with maturation of the vascular system, endothelial flk-1 mRNA 
expression regressed over time (Figure 15, ED 17.5-P14).  
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Figure 15: Spatiotemporal flk-1 mRNA expression during lung development  
Radioactive [35S]α−UTP-labeled mRNA in situ hybridization for flk-1 mRNA, on C57bl 6 
mouse embryonic and postnatal tissues. Sections are shown in light field, with blue nuclear 
staining and dark field for mRNA probe signal for antisense (AS) and sense (S) probes from 
ED12.5 until P1 and P14. Flk-1 mRNA is expressed from ED12.5 throughout ED16.5 in the 
vascular network (depicted by white and black arrowhead, white spots of AS probe). At 
ED16.5, flk-1 expression was present in the epithelial cells of bronchial tubes (indicated by 
white and black arrows). The epithelial flk-1 expression persisted until later stages and was 
restricted to single cells in the alveolar regions of postnatal day. (ED = embryonic day; P = 
postnatal day). 
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5.1.2. Flk-1 protein expression during lung development 
The localization of flk-1 protein expression was assessed by immunohistochemistry and 
confocal laser scanning microscopy. Embryonic mouse lungs of C57bl 6 mice at ED14.5 and 
ED18.5 as well as adult mouse lung tissue (12 weeks of age) were investigated. Cellular 
phenotyping for specific endothelial and epithelial cell protein expression in combination with 
flk-1 detection confirmed the flk-1 mRNA expression pattern derived from the in situ 
hybridization experiments. During the early embryonic stages (ED14.5 to ED16.5) flk-1 
protein expression was exclusively co-localized with the endothelial marker CD 31 in the 
vascular networks (Figure 16, A), whereas no flk-1 immunoreactivity could be detected in 
cytokeratin-positive epithelial cells (Figure 16, D-F). From ED17.5 onwards, co-expression of 
flk-1 and cytokeratin was localized to the bronchial tubules and primordial gas exchange 
regions (Figure 16, G-I). In adult lung tissue, flk-1 was predominantly expressed in airway 
epithelial cells (Figure 16, J-L). Staining with respective IgG controls did not show any 
immunoreactivity. 
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Figure 16: Epithelial and endothelial flk-1 protein expression in lung development 
Confocal laser scanning microscopy of immunoreactivity for flk-1 (red) on C57bl 6 mouse 
embryonic (ED14.5, ED18.5) and adult tissue in combination with CD 31 (green; A, B, C), 
cytokeratin (green; E, F, H, I, K, L), nuclear staining with Topro-3 (blue) (A-C, F, I, L,). Flk-
1 co-localized with CD31 at ED14.5 in the developing vascular network (yellow, white 
arrowhead with asterix in A, but not with cytokeratin in the early bronchial tube (white arrow 
in D-F). At ED18.5 and in the adult mouse lung, flk-1 was coexpressed with cytokeratin in the 
bronchial tubes (white arrow in G-L) but not with CD 31 in the larger vessels (arrowhead in B 
and C), whereas co-localization of flk-1 and CD 31 persisted in the capillaries in adult lung 
tissue (arrowhead with asterix in C).  
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5.1.3. Flk-1 expression and receptor phosphorylation in isolated AEC 
To elucidate the functional role of flk-1 expression, we isolated AEC from adult C57bl 6 
mice. Endothelial cell contamination of the AEC culture was excluded by absence of cells 
immunoreactive for CD 31 (a specific endothelial cell marker) and revealed a purity of >95% 
(data not shown). Immunocytochemistry of AEC, 48 and 72 h post isolation, revealed co-
expression of flk-1 with the epithelial cell markers proSPC and cytokeratin (Figure 17 A-F). 
Immunoreactivity of respective IgG controls was not detectable. Immunoprecipitation of flk-1 
from isolated AEC lysates followed by western blot analysis for flk-1 further confirmed 
VEGFR-2 expression in these cells (Figure 17 G). To investigate the functional activity of flk-
1 in AEC, isolated AEC were treated with 100 ng/ml VEGF-A. Immunoprecipitation of flk-1 
from cell lysates and western blot analysis for phosphotyrosine showed a clear increase of the 
phosphorylation state of the receptor compared to the non stimulated control (Figure 17 H).  
5.1.4. Freshly isolated alveolar epithelial cells constitutively secrete 
VEGF-A  
To examine whether AEC also secrete VEGF-A, supernatants were collected from isolated 
AEC after 72 h of culture and subjected to VEGF-A ELISA. The VEGF-A concentration in 
the supernatant was 128.3 ± 5.6 pg/ml (Figure 17 I). 
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Figure 17: Flk-1 protein expression in AEC  
A-F: Immunofluorescent staining of isolated alveolar epithelial cells from C57bl 6 mice at 48 
(A-C) and 72 h (D-F) after isolation. Immunoreactivity is shown for flk-1 (red: B, C, E, F), 
prosurfactant protein C (proSPC, green; A, C) and cytokeratin (green; D, F). Flk-1 was 
present in proSPC- and cytokeratin-immunoreactive cells (overlays in C and F). G-I: Flk-1 
expression and receptor phosphorylation in isolated alveolar epithelial cells (AEC). 
Immunoprecipitation of flk-1 protein from lysates of murine alveolar epithelial cells 72 h post 
isolation. Western blot of the precipitate for flk-1 shows the presence of flk-1 in AEC (G). 
Blotting the precipitate for phosphotyrosine with and without prior VEGF application (100 
ng/ml VEGF-A for 1 min) revealed constitutive flk-1 receptor phosphorylation that was 
significantly enhanced by VEGF stimulation (H). The constitutive secretion of VEGF-A by 
AEC was shown by ELISA for murine VEGF-A from supernatants (sn) of isolated alveolar 
epithelial cells and unconditioned media (ctr) as control after 72 h of incubation (I.). *, p<0.01 
(N=3). 
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5.2. HIF 2 α expression in isolated adult AEC  
5.2.1. HIF 2 α expression in isolated AEC 
To investigate the role of the HIF 2 α flk-1 system in AEC, we primarily wanted to examine 
HIF 2 α expression in these cells. Accordingly, we isolated AEC and examined HIF 2 α 
expression at the protein level. Immunocytological staining with a rabbit anti-HIF 2 α 
antibody and secondary Alexa 488®-labeled anti-rabbit antibody yielded a strong green signal 
in these isolated AEC (Figure 18 A and C). Staining with rabbit IgG control antibody and a 
secondary Alexa 488®-labeled anti-rabbit antibody did not give any signal (Figure 18 B and 
D). 
 
Figure 18: HIF 2 α protein expression in isolated AEC 
Immunofluorescent staining of isolated alveolar epithelial cells from C57bl 6 mice 72 h (A-D) 
after isolation. Immunoreactivity is shown for anti-HIF 2 α (green, A, C) and rabbit IgG 
(green; B,D). HIF 2 α was present in these isolated AEC (A and C). Rabbit IgG did not give 
any signal (B, D). Topro-3 was used for nuclear staining (blue). 
5.2.2. HIF 2 α protein expression in adult AEC and intracellular 
distribution under normoxic and hypoxic conditions  
To confirm the expression of HIF 2 α in isolated AEC as shown by immunocytochemistry, 
lysates of AEC cultured under normoxic and hypoxic conditions were subjected to western 
blot analysis for HIF 2 α. Lysates were prepared and separated for nuclear and cytosolic 
fractions. Under normoxic conditions, HIF 2 α was highly expressed in the cytosolic fraction, 
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but not in the nuclear fraction (Figure 19). Hypoxic culture conditions led to an increase in 
HIF 2 α signal in the nuclear fraction with stable expression in the cytosolic fraction. α 
tubulin and C 23 expression, respectively, represented the purity of nuclear and cytosolic 
fractions (Figure 19). 
 
Figure 19: HIF 2 α protein expression in adult AEC under normoxic and hypoxic cell-
culture conditions 
Lysates of isolated AEC from C57bl 6 mice after 72 h of culture were prepared and separated 
into cytosolic and nuclear fractions and subjected to western blot analysis. Under normoxic 
conditions, HIF 2 α was expressed in the cytosolic, but not in the nuclear fraction. Hypoxic 
conditions led to a HIF 2 α signal in the nuclear and cytosolic fraction. Expression of α-
tubulin and C 23, respectively, indicated the purity of the cytosolic and nuclear fraction. 
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5.3. Generation of an in vivo inducible pulmonary epithelial HIF 2 α 
knock-out mice 
5.3.1. Genotyping of triple transgenic SPCrtTA-tetO-Cre-HIF 2 α loxP 
mice 
To generate an inducible pulmonary epithelial knock-out of HIF 2 α, we generated a triple 
transgenic line combining SPCrtTA-tetO-Cre mice and HIF 2 α loxP mice. Homozygous HIF 
2 α loxP mice were bred with SPCrtTA-tetO-Cre mice. The offspring were genotyped for all 
three transgenes (Figure 20 A-C). Triple transgenic heterozygous HIF 2 α loxP SPCrtTA-
tetO-Cre mice were intercrossed to generate homozygous HIF 2 α loxP SPCrtTA-tetO-Cre 
mice. Offspring were genotyped (Figure 20 D-E) to choose homozygous HIF 2 α loxP 
SPCrtTA-tetO-Cre for further mating procedures with induction of Cre recombinase 
expression. 
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Figure 20: Generation of triple transgenic homozygous HIF 2 α SPCrtTA-tetO-Cre mice  
A-C: Homozygous HIF 2 α loxP mice were crossed with SPCrtTA-tetO-Cre mice to generate 
heterozygous HIF 2 α loxP SPCrtTA-tetO-Cre mice. The offspring were genotyped for all 
three genes: A: PCR of the HIF 2 α loxP locus, showing heterozygous mice (lanes 1-3, 5-6)  
and positive control of homozygous (lane 7) heterozygous (lane 8) and wild-type mice (lane 
9) and negative control (lane 10). B: PCR for the SPCrtTA locus showing positive (lanes 1-2), 
negative mice (lanes 3-8), negative control and positive control (lane 9-10). C: PCR for the 
tetO-Cre locus showing positive (lanes 2-4, 6) negative (lane 1, 5, 7-8), negative and positive 
control (lane 9-10). D-F: Heterozygous HIF 2 α loxP SPCrtTA-tetO-Cre mice (A-C lane 2) 
were intercrossed to generate homozygous HIF 2 α loxP SPCrtTA-tetO-Cre mice. The 
offspring were genotyped for all three transgenes: D: PCR for the HIF 2 α loxP locus showing 
homozygous (lanes 1-2) and heterozygous (lanes 3-5) mice. Accordingly, positive control of 
homozygous (lane 7) heterozygous (lane 8) and wild-type mice (lane 9) and negative control 
(lane 10) were utilized as controls. E: PCR for the SPCrtTA locus showing positive (lanes 1-
2, 4, 6) negative mice (lanes 3, 5, 7, 8), negative control and positive control (lanes 9-10). F: 
PCR for the tetO-Cre locus showing positive lane 1-3, 5 negative lane 4, 6-8, negative and 
positive control lane 9-10. 
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5.3.2. Generation of pulmonary epithelial HIF 2 α knock-out mice  
To generate pulmonary epithelial HIF 2 α knock-out mice, homozygous HIF 2 α loxP 
SPCrtTA-tetO-Cre mice were intercrossed. Cre recombinase expression was induced from 
embryonic day 0 (ED0) by feeding the breeding pair with dox. The offspring were genotyped 
for all transgenes (Figure 21 A-C). Homozygous HIF 2 α loxP SPCrtTA but tetO-Cre 
negative mice were utilized as control mice. At the age of 12 weeks, mice were sacrificed and 
AEC were isolated and cultured for 72 h hours. The DNA was isolated and PCR for the HIF 2 
α loxP locus was performed to investigate Cre excision. Homozygous HIF 2 α loxP 
SPCrtTA-tetO-Cre mice showed the one loxP band (1loxP) according to DNA recombination 
level and the double loxP band (2loxP) (Figure 21 D lane 1-3). Control mice did not show the 
one loxP band due to the lack of DNA recombination (Figure 21 D lane 4-5). To confirm the 
DNA recombination in the AEC of homozygous SPCrtTA-tetO-Cre mice, we isolated DNA 
and performed Southern blot analysis. Homozygous SPCrtTA-tetO-Cre mice showed the one 
loxP and double loxP band in the Southern blot analysis (Figure 21 E lane 2). Control mice 
exclusively showed the double loxP band (Figure 21 E lane 1). 
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Figure 21: Generation of pulmonary epithelial HIF 2 α knock-out mice 
A-C: Homozygous HIF 2 α loxP mice were intercrossed, and the breeding pairs were fed with 
dox to induce Cre expression from ED0. The offspring were genotyped for all three genes: A: 
PCR of the HIF 2 α loxP locus, showing homozygous mice (lanes 1-5) and positive controls: 
homozygous (lane 8) heterozygous (lane 7) and wild-type mice (lane 6) and negative control 
(lane 99. B: PCR for the SPCrtTA locus showing positive (lanes 1-3), negative (lanes 4-7), 
negative control and positive control (lanes 8, 9). C: PCR for the tetO-Cre locus showing 
positive (lanes 1-6), positive and negative control (lanes 7, 8). D, E: To investigate DNA 
recombination due to Cre expression, AEC from homozygous HIF 2 α loxP SPCrtTA-tetO-
Cre mice and control homozygous HIF 2 α SPCrtTA-tetO-Cre mice were isolated and 
cultured for 72 h in dox-containing media. DNA was isolated and PCR for the HIF 2 α loxP 
locus was performed. D: Homozygous HIF 2 α loxP SPC rtTA –tetO-Cre mice showed the 
1loxP band according to the DNA recombination (lanes 1-3) and the 2loxP band (lanes 1-3). 
Control mice did exclusively show the 2loxP band (lanes 4-5), positive and negative controls 
(lanes 6-9). E: To confirm this, Cre-induced DNA recombination, Southern blot analysis was 
utilized: Homozygous HIF 2 α loxP SPC rtTA-tetO-Cre mice showed the 1loxP band and the 
2loxP band (lane 2), whereas control mice exclusively show the 2loxP band (lane 1). 
 5. Results 69 
5.3.3. Confirmation of HIF 2 α deletion at the protein level in pulmonary 
epithelial HIF 2 α knock-out mice 
To confirm the pulmonary epithelial deletion of HIF 2 α in homozygous HIF 2 alpha 1 loxP 
SPCrtTA-tetO-Cre mice AEC of adult homozygous HIF 2 α 1loxP SPCrtTA-tetO-Cre mice 
were isolated and cultured for 72 h in dox-containing media. Protein was isolated and a 
western blot for HIF 2 α was performed. Homozygous HIF 2 α 2 loxP SPC-rtTA mice were 
chosen as control mice, which showed a strong signal for HIF 2 α at 100 kDa (Figure 22). 
Epithelial HIF 2 α knock-out mice did not give a signal for HIF 2 α compared to α-tubulin 
and to control mice (Figure 22). 
 
Figure 22: Confirmation of pulmonary epithelial HIF 2 α  gene deletion at the protein 
level in epithelial HIF 2 α knock-out mice 
To confirm the epithelial HIF 2 α deletion in epithelial HIF 2 α knock-out mice, AEC of 
homozygous HIF 2 α 1loxP SPCrtTA-tetO-Cre mice (ko) and homozygous HIF 2 α 2loxP 
SPCrtTA mice as control mice (ctr) were isolated and cultured for 72 h in dox-containing 
media. Protein was isolated and a western blot for HIF 2 α was performed. Control mice 
showed a strong signal for HIF 2 α at 100 kDa whereas epithelial HIF 2 α knock-out mice did 
not give a signal for HIF 2 α while the signal for α-tubulin remained stable. 
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5.4. Phenotype of pulmonary epithelial HIF 2 α knock-out mice 
Induction of the deletion from the first day of embryonic development initially did not give 
rise to any specific phenotype. Pulmonary epithelial HIF 2 α knock-out mice were born at 
term and breathed normally, without any signs of cyanosis. To further analyze the effects of 
the pulmonary epithelial HIF 2 α deletion, AEC were further analyzed for differences in 
protein expression of flk-1 and SPC respectively. Furthermore, lung morphometric analysis 
and electron microscopy of epithelial HIF 2 α knock-out lungs compared to control lungs was 
performed. 
5.4.1. Epithelial flk-1 expression in pulmonary epithelial HIF 2 α knock-
out mice 
To elucidate the impact of pulmonary epithelial HIF 2 α knock-out on flk-1 expression, AEC 
from adult homozygous HIF 2 α 1loxP SPC rtTA-tetO-Cre mice and homozygous HIF 2 α 
2loxP SPCrtTA mice (as control mice) were isolated and cultured in dox-containing media. 
Protein was isolated and a western blot for flk-1 was performed. Control mice showed a 
strong signal for flk-1 at 200 kDa. In contrast, pulmonary epithelial HIF 2 α knock-out mice 
did show a strong reduction of flk-1 signal, while the signal for α-tubulin remained 
unchanged (Figure 23). 
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Figure 23: Epithelial flk-1 expression in pulmonary epithelial HIF 2 α knock-out mice 
 To elucidate the impact of pulmonary epithelial HIF 2 α knock-out on epithelial flk-1 
expression, western blot was performed on isolated and cultured AEC from control and 
pulmonary epithelial HIF 2 α knock-out mice: Control mice (ctr) showed a strong signal for 
flk-1 at 200 kDa. In contrast, pulmonary epithelial HIF 2 α knock-out mice (ko) showed a 
strong reduction in flk-1 signal, while the α-tubulin signal remained unchanged. 
 5.4.2. Epithelial SPC expression in pulmonary epithelial HIF 2 α knock-
out mice 
To elucidate the influence of pulmonary epithelial HIF 2 α knock-out on SPC expression, 
AEC from adult homozygous HIF 2 α 1loxP SPC rtTA-tetO-Cre mice and homozygous HIF 2 
α 2loxP SPC rtTA mice as (control mice) were isolated and cultured in dox-containing media. 
Protein was isolated and a western blot for SPC was performed. Control mice and epithelial 
HIF 2 α knock-out mice showed a strong signal for SPC at 25 kDa. The signal for α-tubulin 
remained unchanged (Figure 24). 
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Figure 24: Epithelial SPC expression in pulmonary epithelial HIF 2 α knock-out mice 
To elucidate the impact of pulmonary epithelial HIF 2 α knock-out on epithelial SPC 
expression, a western blot of isolated and cultured AEC from control (ctr) and pulmonary 
epithelial HIF 2 alpha knock-out mice (ko) was performed. Control mice and pulmonary 
epithelial HIF 2 α knock-out mice showed a strong signal for SPC at 25 kDa. The α-tubulin 
signal remained unchanged. The flk-1 signal was reduced in all epithelial HIF 2 α knock-out 
mice. 
5.4.3. Lung morphometry analysis in adult pulmonary epithelial HIF 2 α 
knock-out mice induced from ED0 compared to control mice  
Lung morphometry analysis were kindly performed by Dipl. Ing. Msc. Biol. Sandeep Nikam. 
 
To investigate the possible impact of the pulmonary epithelial HIF 2 α deletion on lung 
morphology, lungs of the pulmonary epithelial HIF 2 α knock-out mice and control mice 
were subjected to lung morphometry analysis. Analysis of total lung volume, alveolar surface 
area and the number of alveoli revealed no differences between pulmonary epithelial HIF 2 α 
knock-out and control mice (Figure 25 A-C). 
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Figure 25: Lung morphometry analysis  
Adult pulmonary epithelial HIF 2 α knock-out mice (n=4) induced from ED0 compared to 
control mice (n=7) were subjected to lung morphometry analysis. A: total lung volume. B: 
total alveolar surface area. C: total alveolar number. 
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5.4.4. Electron microscopy of AEC of adult pulmonary epithelial HIF 2 α 
knock-out mice induced from ED0 compared to control mice 
 
Analysis by electron microscopy was kindly performed by Prof. Dr. Wolfgang Kummer, 
Institute for Anatomy and Cell Biology, University of Giessen, Germany. 
 
Lungs of pulmonary epithelial HIF 2 α knock-out mice were subjected to electron microscopy 
to analyze alveolar type two cell morphology. Control mice (n=5) showed a regular alveolar 
type two cell structure with regular type two cell features (Figure 26 A). The cell organelles, 
such as laminar bodies and mitochondria, showed a normal physiological structure. The same 
characteristic features were observed in alveolar type two cells of pulmonary epithelial HIF 2 
α knock-out mice (Figure 26 B). No changes could be observed upon HIF 2 α deletion. 
 
Figure 26: Electron microscopy  
Adult pulmonary epithelial HIF 2 α knock-out mice (n=5) induced from ED0 and control 
mice (n=5) were analyzed by electron microscopy (EM) with emphasis on the alveolar 
epithelial cell morphology. No differences in the morphology between the pulmonary 
epithelial HIF 2 α knock-out (B) and the control (A) mice were detected. 
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6. Discussion 
In the present study we investigated the possible role of the pulmonary epithelial HIF 2 α flk-
1 system during lung development. In the first part we characterized flk-1 expression at daily 
intervals from ED12.5 throughout lung development until postnatal stages, and in isolated 
alveolar epithelial cells from adult mice. As a result we demonstrated widespread epithelial 
flk-1 expression in mice commencing around ED17.5 and persisting postnatally (Ahlbrecht et 
al., 2008). To our knowledge, this is the first murine study characterizing epithelial flk-1 
expression at daily intervals throughout lung organogenesis, until birth, and at later postnatal 
stages. In comparison with the early endothelial flk-1 expression which has been described 
previously (Flamme et al., 1995), the epithelial expression appears in the later stages of lung 
development. Since it has been shown that flk-1 is highly regulated by HIF 2 α (Elvert et al., 
2003) we looked at HIF 2 α expression in AEC. We found strong expression at the protein 
level in isolated alveolar epithelial cells (Figure 18 and Figure 19). Accordingly, we 
hypothesized that pulmonary epithelial HIF 2 α knock-out would lead to a severe phenotype 
by a consequent reduction in flk-1 expression. Thus, in the second part of our study, we 
generated inducible pulmonary epithelial-specific HIF 2 α knock-out mice to elucidate 
epithelial HIF 2 α function. Induction of the deletion from the first day of embryonic 
development did not yield any specific phenotype. Pulmonary epithelial HIF 2 α knock-out 
mice were born at term, and were breathed normally. This was unexpected, because 
Compernolle et al reported a severe respiratory distress syndrome upon homozygous HIF 2 α 
deletion (Compernolle et al., 2002). Analysis of lung morphometry revealed no change in 
lung structure upon pulmonary epithelial HIF 2 α deletion, even though flk-1 expression in 
isolated alveolar epithelial cells was highly downregulated. 
6.1. Flk-1 expression during lung development 
The development of the vasculature is a key process in lung development. Angiogenesis and 
vasculogenesis are detected at early stages of lung development (Gebb and Shannon, 2000), 
and, VEGF-A has been shown to be a central growth factor regulating physiological and 
pathological  vascular development (Carmeliet, 2005; Mustonen and Alitalo, 1995; Risau and 
Flamme, 1995). Accordingly, flk-1 has been shown to be expressed in the early primitive 
vascular network as a key receptor mediating these angiogenic signals (Flamme et al., 1995; 
Yamaguchi et al., 1993). In the present study, we characterized flk-1 expression from ED12.5 
throughout lung development at daily intervals and at postnatal stages. We found flk-1 
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expression throughout the early stages restricted to the early endothelial system (Figure 15). 
This is in line with the previous reported flk-1 expression pattern (Flamme et al., 1995; 
Yamaguchi et al., 1993). Furthermore, our data demonstrate epithelial flk-1 expression 
commencing around ED16.5 (Figure 15). Interestingly, this epithelial flk-1 expression appears 
around the transition from the pseudoglandular to the canalicular stage. This period has been 
described as marked by the birth of the acinus (Burri in: McDonald, 1997 p.4-6). 
Furthermore, epithelial cells which are loaded with glycogen, which is the key substance 
required for further cell differentiation (Burri in: McDonald, 1997 p. 4-6), appear at this stage. 
Thus, epithelial flk-1 expression as demonstrated by our data might have impact on epithelial 
differentition. Some reports show flk-1 expression in isolated ED19 rat alveolar epithelial 
type two cells (Raoul et al., 2004) and in epithelial cells of human fetal lung explants (Brown 
et al., 2001), however, our data are the first murine data characterizing the epithelial flk-1 
expression at daily intervals throughout lung development and until postnatal stages 
(Ahlbrecht et al., 2008). Due to this epithelial expression, we suggested a further role of flk-1 
during lung development, which is not restricted to the endothelial system. Accordingly, there 
is recent discussion about the role of flk-1 in branching morphogenesis. Del Moral et al. have 
demonstrated increased epithelial branching morphogenesis in whole lung culture in response 
to VEGF-A treatment at ED11. In contrast, isolated endodermal cells did not respond to 
VEGF-A treatment, whereas differentiation of isolated flk-1-positive cells was increased upon 
VEGF-A treatment (Del Moral et al., 2006). While this provides evidence for an indirect 
effect of endothelial flk-1 on the epithelial system, our data suggest a more direct role of flk-1 
on the epithelial system. Another role of flk-1 was postulated by Gebb and Shannon, who 
suggested that due to spatial juxtaposition of mesenchymal flk-1-positive and epithelial cell, 
signals from the epithelium may be directing pulmonary vascularization. Furthermore, they 
demonstrated flk-1 mRNA expression postnatally in the alveoli of rats (Gebb and Shannon, 
2000). There are further studies focusing on the role of flk-1 in the crosstalk between the 
vascular and the epithelial system. Tuyl et al. inhibited vascular development by antisense 
oligonucleotides directed against VEGF, which lead to reduced epithelial branching (van Tuyl 
et al., 2005), and Yamamoto et al suggested that primary septa formation is dependent on 
reciprocal interactions between respiratory epithelium and the underlying vasculature. They 
selectively inactivated the VEGF gene in the pulmonary epithelial system, which resulted in a 
complete absence of pulmonary capillaries. This further led to a disruption of primary septa 
formation (Yamamoto et al., 2007). Similar effects were described by Zhao et al., using a 
soluble receptor in lung renal capsule graft, they inhibited VEGF-A activity which led to 
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inhibition of vascular development with secondary alterations to epithelial proliferation and 
sacculation (Zhao et al., 2005). There are further studies focusing on the role of VEGF in lung 
development (Akeson et al., 2005; Akeson et al., 2003; Le Cras et al., 2004; Zeng et al., 
1998). However, the majority of these studies point out the importance of epithelial VEGF 
and endothelial flk-1 for branching morphogenesis and septa formation, but do not focus on 
the direct epithelial role of flk-1 which is suggested by our data. In contrast, investigations by 
Raoul et al. revealed an increase in surfactant protein B transcripts in isolated rat fetal alveolar 
epithelial cells in response to VEGF-A stimulation, and demonstrated epithelial flk-1 
expression in these cells (Raoul et al., 2004). This supports our hypothesis of a unique 
epithelial function of flk-1. Furthermore, Brown et al. showed immunoreactivity for flk-1 in 
the distal epithelial cells of human fetal lung explants, and an increase in SPA and SPC 
expression in these cells upon VEGF-A treatment (Brown et al., 2001). Thus, this is another 
hint supporting our hypothesis of epithelial flk-1 function. To further follow this hypothesis, 
we analyzed isolated adult alveolar epithelial cells for flk-1 expression. 
6.2. Flk-1 expression and VEGF–A secretion in isolated AEC of adult 
C57bl 6 mice 
To further investigate our hypothesis of a unique role of epithelial flk-1 expression we 
isolated adult alveolar epithelial cells of C57bl 6 mice. As a result, we found strong 
immunoreactivity for flk-1 in the immunocytology. This expression could be confirmed by 
western blot analysis. These results are in line with findings by Raoul et al. and Brown et al., 
where both groups showed immunoreactivity for flk-1 in isolated fetal rat alveolar epithelial 
cells and human fetal lung explants (Brown et al., 2001; Raoul et al., 2004). But these studies 
did not confirm flk-1 expression by western blot analysis. To further prove regulation 
integrity of epithelial flk-1 expression, we analyzed flk-1 activation by VEGF-A treatment of 
these cells. VEGF-A treatment resulted in an increase of flk-1 phosphorylation 1 min after 
stimulation. Taken together, we demonstrated flk-1 expression and regulation which has not 
been demonstrated for the pulmonary epithelial system before. Since flk-1 could be activated 
in these cells, we suggested an autocrine loop of the VEGF-A flk-1 system in these cells. 
Thus, we investigated VEGF-A secretion of these isolated AEC. We found significantly 
higher VEGF-A concentrations in the supernatant of these cells, compared to unconditioned 
media as a control. Since we characterized an intact VEGF-A/flk-1 ligand receptor system in 
the murine alveolar epithelial system, we hypothesized a functional impact of this system on 
lung development. Data by Compernolle et al. support this hypothesis, where the development 
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of a severe respiratory distress syndrome upon HIF 2 α deletion was demonstrated, which 
could be prevented by VEGF treatment. Furthermore, they demonstrated that intrauterine 
delivery of anti flk-1 antibodies caused respiratory distress syndrome (Compernolle et al., 
2002). Since flk-1 has been shown to be regulated by HIF 2 α (Elvert et al., 2003) the severe 
phenotype of these HIF 2 α knock-out mice might be caused by reduction of flk-1. In deed in 
the study of Compernolle et al. the respiratory distress syndrome was accompanied by severe 
epithelial dysfunction. Thus, this is a further hint supporting epithelial function of flk-1. To 
analyze this, we investigated HIF 2 α expression in isolated AEC as a key regulator of the 
VEGF-A flk-1 system. 
6.3. HIF 2 α expression in isolated AEC of C57bl 6 mice 
Due to our data on epithelial flk-1 expression, we hypothesized that the pulmonary phenotype 
of global HIF 2 α knock-out mice (Compernolle et al., 2002) was strongly influenced by the 
loss of the epithelial HIF 2 α flk-1 system. Supporting this hypothesis, Ema et al. showed 
epithelial Hif 2 alpha expression (Ema et al., 1997). Furthermore Wagner et al. 2004 showed 
Hif 2 α expression in the canalicular phase in the bronchial epithelium and in septal cells 
(Wagner et al., 2004). Accordingly, we analyzed isolated AEC of C57bl 6 mice for HIF 2 α 
expression. We found strong immunoreactivity for HIF 2 α in these isolated cells. 
Investigations on hypoxic regulation of HIF 2 α showed that Hif 2 α was expressed in the 
AEC and nuclear translocation was induced by hypoxia as described for hypoxia-inducible 
factors (Semenza et al., 1991). Taken together, we demonstrated alveolar epithelial expression 
of all three components of the HIF 2 α/flk-1/VEGF system. To elucidate the functional 
impact of this system on lung development, we generated an in vivo inducible epithelial 
deletion of HIF 2 α using a triple transgenic approach combining the rtTA and the Cre loxP 
sytem. 
6.4. Pulmonary epithelial HIF 2 α knock-out 
To investigate the role of the pulmonary epithelial HIF 2 α/flk-1 system we generated an in 
vivo pulmonary epithelial HIF 2 α deletion in a triple transgenic murine approach. The 
deletion was caused by DNA recombination. Even partial DNA recombination as 
demonstrated by PCR (Figure 21 D) and Southern blot (Figure 21 E) led to a strong reduction 
of HIF 2 α at the protein level (Figure 22) in isolated AEC of induced triple transgenic mice 
compared to control mice. HIF 2 α deletion induced from ED0 on did not cause a specific 
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disorder or phenotype. This was unexpected, because we hypothesized a key function of the 
epithelial HIF 2 α flk-1 system during lung development. Thus, we expected a severe disorder 
in phenotype upon epithelial HIF 2 α deletion. Global HIF 2 α deletion in vivo as shown by 
Compernolle et al. led to a severe respiratory distress syndrome (Compernolle et al., 2002). 
Since the respiratory distress syndrome was accompanied by severe epithelial defect in that 
study, we hypothesized that this phenotype was mainly induced by the epithelial HIF 2 α flk-
1 system. But our data demonstrated contradictory effects: even during further postnatal 
development, no developmental disorders could be detected. Taken together, we succeeded in 
generating an in vivo inducible epithelial HIF 2 α deletion using a transgenic approach 
combining the rtTA and Cre-loxP system. Surprisingly, this pulmonary epithelial HIF 2 α 
deletion did not impact regular lung development. To further investigate the influence of 
pulmonary epithelial HIF 2 α deletion we looked at flk-1 and SPC expression in isolated AEC 
of pulmonary epithelial HIF 2 α knock-out mice. Furthermore we subjected pulmonary 
epithelial HIF 2 α knock-out lungs to morphometric analysis and electron microscopy.  
6.5. Phenotype of pulmonary epithelial HIF 2 α knock-out mice 
Triple transgenic mice in which pulmonary epithelial HIF 2 α had been ablated mice did not 
show a distinct disorder or phenotype at birth. Even further postnatal development was 
regular, and the animals grew without any obvious defects. This was an unexpected result, 
because due to the pulmonary phenotype of global HIF 2 α knock-out mice reported by 
Compernolle et al. (Compernolle et al., 2002), we postulated a key role of the epithelial HIF 2 
α flk-1 system in lung development. We demonstrated the epithelial expression of the system, 
and we succeeded in generating a complete epithelial HIF 2 α deletion. But the expected 
disorder in pulmonary phenotype was not observed in the epithelial knock-out animals. Even 
though western blot analysis of the isolated AEC did reveal a consequent reduction of flk-1 
protein upon HIF 2 α deletion, the expected changes in epithelial function were absent. In 
contrast to data presented by Raoul et al. and Brown et al., who showed regulation of 
surfactant proteins upon VEGF-A treatment in AEC from rats and humans (Brown et al., 
2001; Raoul et al., 2004), our data showed no change in SPC expression levels upon HIF 2 α 
deletion in the isolated AEC isolated from pulmonary epithelial HIF 2 α knock-out mice 
compared to control mice. These differences might be due to interspecies differences, but this 
is highly speculative. A further possible explanation might be a strong influence of the 
different background of the triple transgenic mice. The SPC/Cre mice were raised on a FVBN 
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background whereas the HIF 2 α loxP mice were raised on a agouti and C57bl 6 background. 
The influence of the murine background has been discussed previously to be the reason for 
the observed differences in the different existing HIF 2 α knock-out strains (Scortegagna et 
al., 2003a). Furthermore, our data on lung morphometry of the pulmonary epithelial HIF 2 α 
knock-out mice revealed no single parameter changed, compared to control mice. Finally, we 
analyzed AEC of these epithelial HIF 2 α knock-out mice by electron microscopy. Again, no 
differences between control and pulmonary epithelial HIF 2 α knock-out mice were observed 
(Figure 26) in particular the laminar bodies appeared regular and unaltered. This again is an 
unexpected result because several reports suggested an impact of the epithelial HIF 2 α/flk-1 
system particular on alveolar type two cell function and surfactant production (Brown et al., 
2001; Compernolle et al., 2002; Raoul et al., 2004). We hypothesized that compensatory 
mechanisms might take over the HIF 2 α function. Thus, we initiated transgene induction 
later at ED17.5 to reduce the time, to limit the possible induction of long term compensatory 
mechanisms, but this did not have a different effect from that at the induction from ED0 on 
(data not shown). Taking together, we characterized the epithelial HIF 2 α/flk-1 system in the 
pulmonary epithelial system. Furthermore we were able to generate a complete pulmonary 
epithelial HIF 2 α deletion which led to consequent reduction in flk-1 expression. But this 
epithelial deletion did not lead to a severe epithelial or developmental defects. This suggests 
that the HIF 2 α/flk-1 system is present in the epithelial system, but its functional impact is 
supported by further factors which were not addressed in the present study. A further 
possibility might be related to technical concerns. As demonstrated by PCR and Southern 
blot, DNA recombination was not completed. However, HIF 2 α and flk-1 protein levels were 
strongly reduced. It might be possible that the remaining epithelial cells without 
recombination were sufficient to recover the HIF 2 α and flk-1 deletion. But this suggestion 
seems to be unlikely because the remaining Hif 2 alpha and flk-1 levels were undetectable, as 
demonstrated by western blot analysis. Thus, it might be suggested that the development of 
the epithelial system is such a pivotal process of lung development that different systems are 
working in parallel to guarantee undisrupted development. Thus, loss of one system can be 
compensated by another system, which has not been discovered. Furthermore, the 
differentiation of the epithelial system appears during a later period of lung development than 
does the differentiation of the early primitive vascular network. Thus, the endothelial deletion 
of HIF 2 α and flk-1 results in a more severe and lethal phenotype during early development 
(Duan et al., 2005; Shalaby et al., 1995). It might be postulated that the possibilities of repair 
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and compensatory mechanisms increase with the age of the developing embryo to protect the 
growing organism, whereas early defects are more likely to result in severe and lethal 
phenotype. Thus the described pulmonary phenotype of the global HIF 2 α knock-out mice as 
demonstrated by Compernolle et al. (Compernolle et al., 2002) appear to be dominated by the 
vascular loss of the HIF 2 α/flk-1 system.  
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7. Summary 
In the present study, we hypothesized that the HIF 2 α/flk-1 system has a unique role in the 
pulmonary epithelial system, with further impact on lung development. This hypothesis was 
based on data by Compernolle et al. showing a severe respiratory distress syndrome upon 
global HIF 2 α deletion which could be overcome by the application of VEGF (Compernolle 
et al., 2002). However, key functions of the HIF 2 α/flk-1 system have been demonstrated to 
be restricted to the vascular system, to regulate physiological and pathological blood vessel 
formation. In contrast, reports by Brown et al. and Raoul et al. suggest a direct influence of 
the flk-1/VEGF system on pulmonary epithelial cell function (Brown et al., 2001; Raoul et al., 
2004). Since flk-1 has been shown to be regulated by HIF 2 α (Elvert et al., 2003) it 
represents the functional target molecule of the HIF 2 α/flk-1 system. Accordingly, we 
characterized flk-1 expression from ED12.5 at daily intervals throughout lung development 
until postnatal stages. We found flk-1 expression, as previously described, in the early 
primitive vascular network. At the end of the pseudoglandular stage, at ED16.5 we found 
widespread epithelial expression of flk-1 which persisted until postnatal stages. Furthermore, 
we analyzed flk-1 expression and functional integrity in isolated adult (Ahlbrecht et al., 
2008). To test our hypothesis of a direct functional impact of the HIF 2 α/flk-1 system on the 
pulmonary epithelial system, we analyzed isolated AEC for HIF 2 α expression, and found 
strong expression of HIF 2 α at the protein level. Thus, we demonstrated that the HIF 2 α/flk-
1 system is not restricted to the endothelial system, and is present in the pulmonary alveolar 
epithelial system. To analyze the functional impact of this newly characterized pulmonary 
epithelial system, we generated an inducible in vivo pulmonary epithelial HIF 2 α deletion 
combining the SPCrtTA and Cre-loxP system. We succeeded in generating the epithelial HIF 
2 α deletion which could be demonstrated at the protein level. But, in contrast to our 
hypothesis that the epithelial HIF 2 α/flk-1 system might have functional impact on lung 
development, epithelial HIF 2 α deletion did not lead to a disorder or phenotype. Even though 
flk-1 was strongly downregulated, no changes were observed regarding lung structure or AEC 
morphology and SPC expression respectively. This was unexpected. Thus we postulate that 
the epithelial HIF 2 α system works within a complex network. Upon HIF 2 α deletion, a 
compensatory system takes over the HIF 2 α-related functions to rescue the deletion to protect 
the process of lung development. This is highly speculative and further investigations are 
needed to characterize the different factors involved which were not addressed in the present 
study.  
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Taken together our study demonstrates: 
Characterization of flk-1 expression at daily intervals throughout lung development with 
epithelial expression of flk-1 rising from ED16.5 and persisting at postnatal stages (Ahlbrecht 
et al., 2008). Furthermore HIF 2 α and flk-1 expression could be demonstrated in isolated 
AEC. Thus, we were able to demonstrate the existence of the epithelial HIF 2 α/flk-1 system.  
Analysis of the direct epithelial function of the newly characterized pulmonary epithelial 
system could be addressed by successful generation of an pulmonary epithelial-restricted HIF 
2 α in vivo deletion using the SPCrtTA-tetO-Cre system. 
Surprisingly, characterization of the phenotype of pulmonary epithelial HIF 2 α knock-out 
mice did not show any disorders or phenotype, or changes in lung structure and epithelial cell 
development. These data may be basis for future studies elucidating the network of 
cooperating factors regulating pulmonary epithelial development. 
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8. Zusammenfassung 
In der vorliegenden Arbeit wird die Hypothese untersucht, dass das HIF 2 α/flk-1 System eine 
eigenständige funktionelle Rolle in dem pulmonalen epithelialen System spielt und darüber 
Einfluss auf die Lungenentwicklung nimmt. Diese Hypothese basiert auf Untersuchungen von 
Compernolle et al. die ein akutes Lungenversagen als Folge einer globalen HIF 2 α Deletion 
beschreiben, welches durch Applikation von VEGF überwunden werden konnte 
(Compernolle et al., 2002). Bisher wurde die Regulation der physiologischen und 
pathologischen Blutgefäßentwicklung als die zentrale Funktion des HIF 2 α/flk-1 Systems 
beschrieben. Die Wirkungsweise schien somit auf das vasculäre System begrenzt zu sein. 
Demgegenüber deuten jedoch Daten von Brown et al. und Raoul et al. darauf hin, dass das 
flk-1/VEGF System auch direkten Einfluss auf die Funktion des pulmonalen epithelialen 
Systems zu nehmen scheint (Brown et al., 2001; Raoul et al., 2004). Flk-1 wird durch HIF 2 α 
reguliert (Elvert et al., 2003) und stellt somit das funktionelle Zielmolekül des HIF 2 α/flk-1 
Systems dar. Diesbezüglich charakterisierten wir in dieser Arbeit zunächst die flk-1 
Expression während der Lungenentwicklung täglich von ED12.5 bis hin zu postnatalen 
Stadien. Als Ergebnis zeigte sich in den frühen Stadien die flk-1 Expression wie bereits 
beschrieben in dem frühen primitiven vasculären Netzwerk. Am Ende der pseudoglandulären 
Phase zeigte sich eine großflächige epitheliale flk-1 Expression, die bis in die postnatalen 
Stadien zu finden war. Des Weiteren konnten wir in murinen isolierten alveolären 
Epithelzellen die flk-1 Expression und Aktivierung nachweisen (Ahlbrecht et al., 2008). 
Darüber hinaus zeigte sich eine starke Expression von HIF 2 α in diesen Zellen. Um die 
Funktion des nun neu charakterisierten pulmonalen epithelialen Systems zu analysieren, 
generierten wir eine in vivo pulmonal epithelzellspezifisches HIF 2 α Deletion mittels 
SPCrtTA- und tetO-Cre System in einem dreifach transgenen Mausmodel. Die erfolgreiche 
Deletion zeigte sich auf Proteinebene. Gegensätzlich zu der zu Grunde liegenden Hypothese 
einer spezifischen Funktion des epithelialen HIF 2 α/flk-1 Systems, zeigte sich jedoch kein 
pathologischer Phenotyp. Es zeigte sich eine stark reduzierte epitheliale flk-1 Expression, die 
sich jedoch nicht auf die Lungenstruktur, Epithelzellmorphologie oder SPC Expression 
auswirkte. Auf Grund dieser unerwarteten Ergebnisse postulieren wir, dass das HIF 2 α/flk-1 
System in ein komplexes Netzwerk von Faktoren integriert ist, welches bei Deletion eines 
Faktors die Funktion übernehmen kann, um eine ungestörte Entwicklung zu ermöglichen. Das 
ist eine spekulative Vermutung, zu deren Klärung weitere Studien notwendig sind, um die 
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unbekannten Faktoren des Netzwerkes zu untersuchen, die in der vorliegenden Arbeit nicht 
untersucht wurden.  
Zusammenfassend konnte die vorliegende Arbeit folgendes zeigen: 
Charakterisierung der flk-1 Expression während der Lungenentwicklung in täglichen 
Intervallen. Es zeigte sich eine epitheliale flk-1 Expression von ED16.5 beginnend und 
persistierend bis zu postnatalen Stadien (Ahlbrecht et al., 2008). Darüber hinaus konnte die 
epitheliale HIF 2 α Expression in isolierten alveolaren Epithelzellen (AEC) gezeigt werden, 
und so die Existenz eines epithelialen HIF 2 α/flk-1 Systems demonstriert werden. 
Als in vivo Model zur funktionellen Analyse des neu charakterisierten pulmonal epithelialen 
Systems konnte eine pulmonal epithelzellspezifische HIF 2 α Deletion mittels SPCrtTA-tetO-
Cre Systems in einem dreifach transgenen Ansatz erzielt werden. 
Entgegen der Hypothese einer speziellen Funktion des epithelialen HIF 2 α/flk-1 Systems 
zeigte sich kein pathologischer Phenotyp unter der epithelspezifischen HIF 2 α Deletion 
bezüglich Lungenstruktur und Epithelzellentwicklung. Diese Daten können eine Basis für 
weitere Studien darstellen, die das Netzwerk der involvierten Faktoren der 
Lungenentwicklung und speziell der pulmonalen Epithelzellentwicklung weiter aufklären.  
. 
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9. Abbreviations 
AEC     alveolar epithelial cells 
AP     alkaline phosphatase 
ARNT     aryl hydrocarbon receptor 
bHLH/PAS    Basic helix-loop-helix/Per Arnt Sim domain 
bp     base pair 
BSA     bovine serum albumin 
C57bl 6    C57 black 6  
CD 31     cluster of differentiation 31 
Cre     Cre recombinase 
cDNA     complemetary deoxyribonucleic acid 
DNA     deoxyribonucleic acid 
dox     doxycycline 
ED     embryonic day 
EDTA     ethylenediaminetetraacetic 
EPO     erythropoietin 
ES     embryonic stem  
FIH      Factor inhibiting HIF 
flk-1     Fetal liver kinase-1/VEGFR-2/KDR 
flt-1      Fms-like tyrosine kinase-1/VEGFR-1 
GFP      green fluorescent protein  
h     hour 
HE     heterozygous 
HLF     HIF like factor 
HO     homozygous 
HRE     hypoxia-responsive element 
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HGF      hepathocyte growth factor 
HIF      hypoxia-inducible factor 
i.p.     intraperitoneal 
kb     kilo base 
kDa     kilodalton 
ko     knock out 
mg     milligram 
µg     microgram 
min     minute 
mRNA    messenger ribonucleic acid 
neo     neomycin 
l     liter 
loxP     recognition site for Cre recombinase 
ODN      oligodeoxynucleotide 
orf     open reading frame 
Orf Virus    Parapox virus 
P     post natal 
pA     polyadenylation site 
PBS     phosphate-buffered saline 
PCI     phenol-chlorophorm-isoamyl alcohol 
PECAM-1    Platelet endothelial cell adhesion molecule-1 
PFA     paraformaldehyde 
proSPC    pro surfactant protein C 
PVDF     polyvinylidene difluoride 
RFP     red fluorescent protein 
RIPA     modified radioimmunoprecipitation 
ROS     reactive oxygen species 
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rtTA     reverse tetracycline transactivator 
s     seconds 
SPC     surfactant protein C 
SPCp     surfactant protein C promoter 
TATA     minimal promoter containing TATA box 
TEA     triethanolamine 
tetO     tet operon 
tetO7     Seven tandemly repeated 19-bp tetO sequence 
tetR     tetracycline repressor 
tk     thymidine kinase 
TSP     tissue-specific promotor 
tTA     tetracycline transactivator 
V     Volt 
VEGF     vascular endothelial growth factor 
VP 16     Transactivationdomain of the herpes simplex virus  
     Protein VP 16 
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